<!doctype html><html><head><title>Myeloma Canvas</title><base href="../"><meta id="root-path" root-path="../"><link rel="icon" sizes="96x96" href="https://publish-01.obsidian.md/access/f786db9fac45774fa4f0d8112e232d67/favicon-96x96.png"><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=yes,minimum-scale=1,maximum-scale=5"><meta charset="UTF-8"><link rel="stylesheet" href="lib/styles/obsidian-styles.css"><link rel="stylesheet" href="lib/styles/theme.css"><link rel="stylesheet" href="lib/styles/plugin-styles.css"><link rel="stylesheet" href="lib/styles/snippets.css"><link rel="stylesheet" href="lib/styles/generated-styles.css"><style></style><script type="module" src="lib/scripts/graph_view.js"></script><script src="lib/scripts/graph_wasm.js"></script><script src="lib/scripts/tinycolor.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/pixi.js/7.2.4/pixi.min.js" integrity="sha512-Ch/O6kL8BqUwAfCF7Ie5SX1Hin+BJgYH4pNjRqXdTEqMsis1TUYg+j6nnI9uduPjGaj7DN4UKCZgpvoExt6dkw==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script src="lib/scripts/webpage.js"></script><script src="lib/scripts/generated.js"></script></head><body class="theme-light show-inline-title loading"><div class="webpage-container"><div class="sidebar-left sidebar"><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div><label class="theme-toggle-container" for="theme_toggle"><input class="theme-toggle-input" type="checkbox" id="theme_toggle"><div class="toggle-background"></div></label></div><div class="tree-container file-tree mod-nav-indicator" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Notes</span><button class="clickable-icon collapse-tree-button is-collapsed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"><div class="tree-item mod-tree-folder mod-collapsible is-collapsed" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link"><div class="tree-item-icon collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle"><path d="M3 8L12 17L21 8"></path></svg></div><span class="tree-item-title">Blog</span></a></div><div class="tree-item-children" style="display:none"><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-1.html"><span class="tree-item-title">Sample 1</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-2.html"><span class="tree-item-title">Sample 2</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-3.html"><span class="tree-item-title">Sample 3</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-4.html"><span class="tree-item-title">Sample 4</span></a></div><div class="tree-item-children"></div></div></div></div><div class="tree-item mod-tree-folder mod-collapsible is-collapsed" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link"><div class="tree-item-icon collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle"><path d="M3 8L12 17L21 8"></path></svg></div><span class="tree-item-title">Plasma Cell Disorders</span></a></div><div class="tree-item-children" style="display:none"><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/active-multiple-myeloma.html"><span class="tree-item-title">Active Multiple Myeloma</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/al-amyloidosis.html"><span class="tree-item-title">AL Amyloidosis</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis-nejm.html"><span class="tree-item-title">Amyloidosis NEJM</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis_-general.html"><span class="tree-item-title">Amyloidosis_ general</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/mgus-monoclonal-gammopathy-of-undetermined-signi.html"><span class="tree-item-title">MGUS - Monoclonal Gammopathy of Undetermined Signi</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/monoclonal-gammopathy-disorders-(fellow).html"><span class="tree-item-title">Monoclonal Gammopathy Disorders (Fellow)</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/myeloma-canvas.html"><span class="tree-item-title">Myeloma Canvas</span></a></div><div class="tree-item-children"></div></div></div></div></div></div></div></div></div></div><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div></div><div class="document-container show"><div class="view-content"><style id="MJX-CHTML-styles"></style><div class="canvas-wrapper node-insert-event" tabindex="-1" style="--zoom-multiplier:1"><svg class="canvas-background"><pattern id="70cd2f3b553e2d12" patternUnits="userSpaceOnUse" x="494" y="0" width="20" height="20"><circle cx="0.7" cy="0.7" r="0.7"></circle></pattern><rect x="0" y="0" width="100%" height="100%" fill="url(#70cd2f3b553e2d12)"></rect></svg><div class="canvas-card-menu" style="z-index:14"><div class="canvas-card-menu-button mod-draggable" aria-label="Drag to add card" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-sticky-note" style="width:24px;max-width:100%"><path d="M15.5 3H5a2 2 0 0 0-2 2v14c0 1.1.9 2 2 2h14a2 2 0 0 0 2-2V8.5L15.5 3Z"></path><path d="M15 3v6h6"></path></svg></div><div class="canvas-card-menu-button mod-draggable" aria-label="Drag to add note from vault" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-file-text" style="width:24px;max-width:100%"><path d="M14.5 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7.5L14.5 2z"></path><polyline points="14 2 14 8 20 8"></polyline><line x1="16" y1="13" x2="8" y2="13"></line><line x1="16" y1="17" x2="8" y2="17"></line><line x1="10" y1="9" x2="8" y2="9"></line></svg></div><div class="canvas-card-menu-button mod-draggable" aria-label="Drag to add media from vault" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-file-image" style="width:24px;max-width:100%"><path d="M14.5 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7.5L14.5 2z"></path><polyline points="14 2 14 8 20 8"></polyline><circle cx="10" cy="13" r="2"></circle><path d="m20 17-1.09-1.09a2 2 0 0 0-2.82 0L10 22"></path></svg></div></div><div class="canvas-controls" style="z-index:14"><div class="canvas-control-group"><div class="canvas-control-item" aria-label="Canvas settings" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-settings" style="width:24px;max-width:100%"><path d="M12.22 2h-.44a2 2 0 0 0-2 2v.18a2 2 0 0 1-1 1.73l-.43.25a2 2 0 0 1-2 0l-.15-.08a2 2 0 0 0-2.73.73l-.22.38a2 2 0 0 0 .73 2.73l.15.1a2 2 0 0 1 1 1.72v.51a2 2 0 0 1-1 1.74l-.15.09a2 2 0 0 0-.73 2.73l.22.38a2 2 0 0 0 2.73.73l.15-.08a2 2 0 0 1 2 0l.43.25a2 2 0 0 1 1 1.73V20a2 2 0 0 0 2 2h.44a2 2 0 0 0 2-2v-.18a2 2 0 0 1 1-1.73l.43-.25a2 2 0 0 1 2 0l.15.08a2 2 0 0 0 2.73-.73l.22-.39a2 2 0 0 0-.73-2.73l-.15-.08a2 2 0 0 1-1-1.74v-.5a2 2 0 0 1 1-1.74l.15-.09a2 2 0 0 0 .73-2.73l-.22-.38a2 2 0 0 0-2.73-.73l-.15.08a2 2 0 0 1-2 0l-.43-.25a2 2 0 0 1-1-1.73V4a2 2 0 0 0-2-2z"></path><circle cx="12" cy="12" r="3"></circle></svg></div></div><div class="canvas-control-group"><div class="canvas-control-item" aria-label="Zoom in" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-plus" style="width:24px;max-width:100%"><path d="M5 12h14"></path><path d="M12 5v14"></path></svg></div><div class="canvas-control-item" aria-label="Reset zoom" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-rotate-cw" style="width:24px;max-width:100%"><path d="M21 12a9 9 0 1 1-9-9c2.52 0 4.93 1 6.74 2.74L21 8"></path><path d="M21 3v5h-5"></path></svg></div><div class="canvas-control-item" aria-label="Zoom to fit
(Shift + 1)" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-maximize" style="width:24px;max-width:100%"><path d="M8 3H5a2 2 0 0 0-2 2v3"></path><path d="M21 8V5a2 2 0 0 0-2-2h-3"></path><path d="M3 16v3a2 2 0 0 0 2 2h3"></path><path d="M16 21h3a2 2 0 0 0 2-2v-3"></path></svg></div><div class="canvas-control-item" aria-label="Zoom out" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-minus" style="width:24px;max-width:100%"><path d="M5 12h14"></path></svg></div></div><div class="canvas-control-group"><div class="canvas-control-item is-disabled" aria-label="Undo" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-undo-2" style="width:24px;max-width:100%"><path d="M9 14 4 9l5-5"></path><path d="M4 9h10.5a5.5 5.5 0 0 1 5.5 5.5v0a5.5 5.5 0 0 1-5.5 5.5H11"></path></svg></div><div class="canvas-control-item is-disabled" aria-label="Redo" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-redo-2" style="width:24px;max-width:100%"><path d="m15 14 5-5-5-5"></path><path d="M20 9H9.5A5.5 5.5 0 0 0 4 14.5v0A5.5 5.5 0 0 0 9.5 20H13"></path></svg></div></div><div class="canvas-control-group"><div class="canvas-control-item" aria-label="Canvas help" data-tooltip-position="left"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-help-circle" style="width:24px;max-width:100%"><circle cx="12" cy="12" r="10"></circle><path d="M9.09 9a3 3 0 0 1 5.83 1c0 2-3 3-3 3"></path><path d="M12 17h.01"></path></svg></div></div></div><div class="canvas" style="transform:translate(494px,0) scale(1) translate(0,0)"><svg class="canvas-edges"></svg><svg class="canvas-edges"></svg><div class="canvas-node" style="z-index:2;transform:translate(-480px,-1240px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Myeloma Master Note
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-01-25 15:21:57Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2022-01-25 14:52:10Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p><strong><a href="#1a" class="tag" target="_blank" rel="noopener">#1a</a> Monoclonal Gammopathy of Undetermined Significance&nbsp;</strong></p></div><div><p>Read more here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/1a1cc2c4-2e13-d69e-4ee9-582c811c11cb/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/1a1cc2c4-2e13-d69e-4ee9-582c811c11cb/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">MGUS - Monoclonal Gammopathy of Undetermined Significance</a></p></div><div><p><strong><a href="#1b" class="tag" target="_blank" rel="noopener">#1b</a> Monoclonal Gammopathy of Renal Significance&nbsp; (MGRS)</strong></p></div><div><p><strong>#2 Smoldering Myeloma</strong><br>**<br>**<br><strong><a href="#3a" class="tag" target="_blank" rel="noopener">#3a</a> Anti-Myeloma Agents</strong><br>**<br>**</p></div><div><p><a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/b7a63fa7-1015-c611-c2c6-09bf0dcd5811/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/b7a63fa7-1015-c611-c2c6-09bf0dcd5811/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Anti-Myeloma Agents</a></p></div><div><p>**<br>**<br><strong><a href="#3b" class="tag" target="_blank" rel="noopener">#3b</a> Active Multiple Myeloma&nbsp;</strong></p></div><div><p>Full article here: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/fb2367a3-8bcf-02b5-b586-84cb215f7b6d/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/fb2367a3-8bcf-02b5-b586-84cb215f7b6d/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Active Multiple Myeloma</a></p></div><div><p>relaps</p></div><div><p><a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/484b3190-3053-ba8c-a046-62dcafe87d5e/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/484b3190-3053-ba8c-a046-62dcafe87d5e/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Multiple Myeloma: Relapsed</a></p></div><div><p><strong>#4 Plasmacytoma</strong><br>**<br>**</p></div><div><p>Full article here: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/71332930-cf8d-1524-ebd6-40dc249c6953/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/71332930-cf8d-1524-ebd6-40dc249c6953/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Plasmacytoma</a></p></div><div><p><strong>#5 Walderstrom Macroglobulinemia&nbsp;</strong><br><strong>(Lymphoplasmacytic Lymphoma)</strong></p></div><div><p>Full article here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/3aea3a19-b71e-ba0c-9168-6fdbc7087175/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/3aea3a19-b71e-ba0c-9168-6fdbc7087175/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Walderstrom Macroglobulinemia&nbsp;(Lymphoplasmacytic Lymphoma)</a></p></div><div><p><strong>#5 Primary Amyloidosis</strong></p></div><div><p>Full article here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/47b1680f-af0c-409b-805a-d81e7b3cf3dd/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/47b1680f-af0c-409b-805a-d81e7b3cf3dd/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">AL Amyloidosis</a></p></div><div><p><strong>#6 Plasma Cell Leukemia</strong></p></div><div><p>Full article here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/4b88f943-f176-29bf-434d-fea87814a8d5/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/4b88f943-f176-29bf-434d-fea87814a8d5/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Plasma Cell Leukemia</a></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Myeloma Master Note</div></div><div class="canvas-node" style="z-index:3;transform:translate(-760px,-684px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><hr></div><div><p>title: Active Multiple Myeloma<br>updated: 2022-01-25 16:09:54Z<br>created: 2021-07-12 23:16:33Z</p></div><div><hr></div><div><p><strong>Definition&nbsp;</strong></p></div><div><ul><li data-line="0">Neoplastic, clonal proliferation of plasma cells producing monoclonal immunoglobulin (usually M protein) resulting in endprognos-organ dysfunction</li><li data-line="1">Usually mono-clonal and secretory</li></ul></div><div><p></p><div width="425" alt="image.png" src="lib\media\image-623.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-623.png" style="max-width:100%"></div><p></p></div><div><p><strong>Epidemiology</strong><br>**<br>**</p></div><div><ul><li data-line="0">Affects older people, median age 68y, M &gt; F, blacks &gt; whites</li><li data-line="1">2% of all cancers in US</li><li data-line="2">Half survive at 5 years</li></ul></div><div><p></p><div width="475" alt="image.png" src="lib\media\image-616.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-616.png" style="max-width:100%"></div><p></p></div><div><p><strong>Variant</strong></p></div><div><p><strong>Non-secretory Myeloma</strong></p></div><div><p>Esp. IgD and IgE<br></p><div width="425" alt="image.png" src="lib\media\image-617.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-617.png" style="max-width:100%"></div><p></p></div><div><p><strong>Plasma Cell Leukemia</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-615.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-615.png"></div><p></p></div><div><p><strong>Pathophysiology</strong><br>**<br>**<br></p><div alt="image.png" src="lib\media\image-(1686297422364).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422364).png"></div><p></p></div><div><ul><li data-line="0"><p>Malignant plasma cell line secretes monoclonal antibody</p></li><li data-line="1"><p><strong>95% produce M protein (</strong>monoclogal Ig = identical heavy chain + identical light chain; OR light chain only)</p><ul><li data-line="2"><p>IgG 50%, IgA 20%, IgD 2%, IgM 0.5%)</p></li><li data-line="3"><p>15-20% produce free <strong>light chains only</strong></p></li><li data-line="4"><p>&lt;5% secrete nothing</p><ul><li data-line="5"><p>Oligosecretory</p></li><li data-line="6"><p></p><div alt="image.png" src="lib\media\image-(1686297425287).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425287).png"></div><p></p></li><li data-line="8"></li></ul></li></ul></li><li data-line="10"><p><strong>Light chains</strong></p><ul><li data-line="11">Found in Serum as Kappa or Lambda light chain. Kappa &gt; lamda has better prognosis</li><li data-line="12">Found in Urine as Bence-Jones protein</li></ul></li></ul></div><div><p><strong>CKD and K/L</strong></p></div><div><ul><li data-line="0">The rapid turnover of FLC (2-6 hours) as compared with IgG (23 days) and other immunoglobulins (ie, Ig: 5.8 days; IgM: 5.1 days; IgD: 2.8 days; IgE: 2.3 days) contribute to FLC lability and thus make it a useful disease burden monitoring tool</li><li data-line="1">Normally, K / L production ratio is 2:1.&nbsp; K/L ratio is &lt; 1 because kappa is a monomer and cleared more readily by kidneys. Under CKD, K/L ratio is &gt;1 because kappa chains cannot be cleared, and both are cleared by the reticuloendothelial system</li></ul></div><div><p><strong>Cytogenetics</strong><br>**<br>**<br></p><div width="525" alt="image.png" src="lib\media\image-388.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-388.png" style="max-width:100%"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-390.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-390.png"></div><div alt="image.png" src="lib\media\image-377.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-377.png"></div><p></p></div><div><p>Molecular characteristics matter, same translocation can be standard or high risk!</p></div><div><p></p><div alt="image.png" src="lib\media\image-385.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-385.png"></div><br>Can relapse with <strong>different </strong>cyogenetics<p></p></div><div><p></p><div alt="image.png" src="lib\media\image-387.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-387.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-391.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-391.png"></div><div alt="image.png" src="lib\media\image-374.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-374.png"></div><div alt="image.png" src="lib\media\image-386.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-386.png"></div><p></p></div><div><p>6% are '<strong>double hit</strong>', with 1q amplification and tp53 mutations</p></div><div><p>MRD After Diagnosis<br></p><div alt="image.png" src="lib\media\image-389.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-389.png"></div><p></p></div><div><p><strong>Diagnosis</strong><br>**<br>**<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297421673).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421673).png" style="max-width:100%"></div><p></p></div><div class="heading-wrapper"><h3 data-heading="**Clinical Features and Complications (SLIM CRAB HANd)**" class="heading" id="**Clinical_Features_and_Complications_(SLIM_CRAB_HANd)**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Clinical Features and Complications (SLIM CRAB HANd)</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><p>*<em><br>**<br></em>amyloidosis, if actually attributable to myeloma, makes you myeloma too!<br>**<br>**</p></div><div><ul><li data-line="0"><p><strong>S</strong> stands for 60%: those patients who have 60% or more clonal plasma cells in the bone marrow were so likely to progress that they ought to be treated and are now classified as symptomatic myeloma</p></li><li data-line="2"><p><strong>Li</strong> stands for light chains: those patients with a kappa-to-lambda or lambda-to-kappa ratio of greater than 100 are so likely to progress to needing treatment that they should be treated at the time of diagnosis</p></li><li data-line="4"><p><strong>M</strong> stands for MRI: patients with more than one focal lesion on MRI now have transitioned from smoldering myeloma to symptomatic disease warranting therapy</p></li><li data-line="5"><p><strong>HyperCalcemia</strong></p><ul><li data-line="6">Bones, groans, moans, stones, psychiatric overtones</li><li data-line="7">Polyuria, polydipsia</li></ul></li><li data-line="8"><p><strong>Renal disease</strong></p><ul><li data-line="9">Cast nephropathy, particularly from light chain disease</li><li data-line="10">BUN to Cr ratio of &lt;20:1 (intinsic injury to kidney)</li><li data-line="11">Immediate treatment: proteasome inhibitor salvages the kidney</li><li data-line="12">Urine sediment should be bland (nephrotic range proteinuria with MGS is uncommon; you need to have a renal biopsy at that point)</li></ul></li><li data-line="13"><p><strong>Anemia</strong></p><ul><li data-line="14">Normocytic anemia</li><li data-line="15">Weakness, fatigue, pallor</li><li data-line="16">From bone marrow suppression</li><li data-line="17">Rouleaux formation</li></ul></li><li data-line="18"><p><strong>Bone Disease (70%)</strong></p><ul><li data-line="19">Pain (back)</li><li data-line="20">Pathological fractures</li><li data-line="21">Lytic lesions (skull, spine, ribs, proximal long bones)</li><li data-line="22">Increased bone resorption secondary to PTHrP</li><li data-line="23">Due to osteoclast activating factor</li><li data-line="24">MIRELS Score</li></ul></li><li data-line="25"><p>Weight loss</p></li><li data-line="26"><p>Infections</p><ul><li data-line="27">S. Pneumo and Gram -, secondary to plasma cell dysfunction</li></ul></li><li data-line="28"><p>Bleeding</p><ul><li data-line="29">thrombocytopenia</li><li data-line="30">acquired vWD</li></ul></li><li data-line="31"><p>Extra-medullary plasmacytoma</p><ul><li data-line="32">Soft tissue mass composed o fmonoclonal plasma cells</li></ul></li><li data-line="33"><p><strong>Hyperviscosity&nbsp;</strong></p><ul><li data-line="34"><p>Strokes, headache, angina, MI</p></li><li data-line="35"><p>M protein hyperviscosity</p></li><li data-line="36"><p></p><div alt="image.png" src="lib\media\image-653.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-653.png"></div><p></p></li><li data-line="38"></li></ul></li></ul></div></div></div><div class="heading-wrapper"><h3 data-heading="**Amyloidosis**" class="heading" id="**Amyloidosis**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Amyloidosis</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><pre><code>- Accumulation of insoluble fibrillar protein (Ig light chain in tissues)
- Cardiac (HFpEF, arrythmias, syncope)
- GI (malabsorption, large tongue)
- Neurologic (orthostatic hypotension, carpal tunnel)
- Factor 10 deficiency (racoon eyes)
</code><button class="copy-code-button">Copy</button></pre></div><div><ul><li data-line="0"><strong>Neurological</strong><ul><li data-line="1">Muscle weakness, pain, parathesia</li><li data-line="2">Spinal cord compression</li><li data-line="3"><em>Nerve entrapment from bone collapse&nbsp;</em></li></ul></li></ul></div></div></div><div class="heading-wrapper"><h3 data-heading="**Revised Staging System for Myeloma (RISS) **" class="heading" id="**Revised_Staging_System_for_Myeloma_(RISS)_**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Revised Staging System for Myeloma (RISS)</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><p></p><div alt="image.png" src="lib\media\image-620.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-620.png"></div><p></p></div><div><p><strong>Risk Stratification</strong></p></div><div><p>The <strong>Medical Research Council IX </strong>trial identified 3 groups:89</p></div><div><ol><li data-line="0"><p><strong>Favorable risk</strong> [no adverse IgH translocation, del(17p), or gain(1q)]</p></li><li data-line="1"><p><strong>Intermediate risk</strong> (1 adverse chromosomal abnormality),</p></li><li data-line="2"><p><strong>High-risk</strong> (&gt; 1 adverse chromosomal abnormality).</p></li><li data-line="4"><p><strong>Ultra-high-risk </strong>was defined as &gt;2 chromosomal aberrations (2% of patients).</p></li></ol></div><div><p>Median progression-free survival (PFS) and OS of patients in the favorable-, intermediate-, and high-risk groups were 23.5, 17.8, and 11.7 months and 60.6, 41.9, and 21.7 months, respectively. Median OS in the ultra-high-risk group was 9 months.</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297228314).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297228314).png"></div><p></p></div><div><p>Memorize the high risk mutations 4;14, 14;16, 17p</p></div><div><p></p><div width="400" alt="image.png" src="lib\media\image-(1686297422163).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422163).png" style="max-width:100%"></div><p></p></div><div><p><strong>Diagnosis</strong><br>**<br>**</p></div><div><ul><li data-line="0">SLIMCRAB + End organ damage (including AL amyloidosis)</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297423832).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423832).png"></div><p></p></div><div><ul><li data-line="0">See main article for investigations</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297422690).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422690).png"></div><p></p></div><div><p><strong>Bone Marrow</strong><br></p><div alt="image.png" src="lib\media\image-(1686297426529).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426529).png"></div><p></p></div><div><p><strong>Staging</strong><br></p><div alt="image.png" src="lib\media\image-(1686297425743).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425743).png"></div><p></p></div></div></div><div class="heading-wrapper"><h1 data-heading="Management" class="heading" id="Management"><div class="heading-before"></div>Management<div class="heading-after">...</div></h1><div class="heading-children"><div><p></p><div width="450" alt="image.png" src="lib\media\image-614.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-614.png" style="max-width:100%"></div><p></p></div><div class="heading-wrapper"><h3 data-heading="**Management: Initial**" class="heading" id="**Management:_Initial**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Management: Initial</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><p>Agents: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/b7a63fa7-1015-c611-c2c6-09bf0dcd5811/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/b7a63fa7-1015-c611-c2c6-09bf0dcd5811/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Anti-Myeloma Agents</a></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297423186).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423186).png"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297421336).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421336).png" style="max-width:100%"></div><p></p></div><div><p></p><div width="400" alt="image.png" src="lib\media\image-(1686297426299).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426299).png" style="max-width:100%"></div><p></p></div></div></div><div class="heading-wrapper"><h2 data-heading="**General Principles**" class="heading" id="**General_Principles**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>General Principles</strong><div class="heading-after">...</div></h2><div class="heading-children"><div><ul><li data-line="0"><p>Non-curative</p></li><li data-line="2"><p>Goals: improve QOL, prevent progression, 3-drug combinations</p></li><li data-line="4"><p>Transplant Eligibility</p><ul><li data-line="5"><div width="500" alt="image.png" src="lib\media\image-(1686297424203).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424203).png" style="max-width:100%"></div></li></ul></li></ul></div><div><p><strong>Big fork: transplant eligible or not</strong><br></p><div width="500" alt="image.png" src="lib\media\image-(1686297420951).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297420951).png" style="max-width:100%"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297423022).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423022).png"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297426111).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426111).png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297421933).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421933).png" style="max-width:100%"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297424399).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424399).png"></div><p></p></div><div><p><strong>Transplant Ineligible:</strong></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297421499).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421499).png" style="max-width:100%"></div><br>Chemotherapy &gt;65 y<p></p></div><div><ul><li data-line="0">3 drug combination as initial therapy --&gt; better OS</li><li data-line="1">lenalidomide, prednisone, bortezomib</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297422860).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422860).png"></div><p></p></div><div><ul><li data-line="0"><p>len/dex/melphalan<br>-</p><div alt="image.png" src="lib\media\image-(1686297425934).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425934).png"></div><p></p><pre><code>  -
</code><button class="copy-code-button">Copy</button></pre></li><li data-line="5"><p>len/daratumumab/dex<br>-</p><div alt="image.png" src="lib\media\image-(1686297423370).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423370).png"></div><p></p></li></ul></div><div><p><strong>Transplant Eligible:</strong><br>**<br>**<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297422525).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422525).png" style="max-width:100%"></div><p></p></div><div><p>Autologous SCT &lt;70?</p></div><div><ul><li data-line="0"><p>High dose chemo induction&nbsp; + Conditioning/Auto-SCT + Maintenance therapy</p><ul><li data-line="1"><p>Induction regimen</p><ul><li data-line="2"><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297424017).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424017).png" style="max-width:100%"></div><p></p></li><li data-line="4"></li></ul></li><li data-line="6"><p>Mixed data for tandem transplant</p></li><li data-line="7"></li><li data-line="8"><p>Lenalidomide Maintenance therapy does improve survival</p><ul><li data-line="9"><p></p><div alt="image.png" src="lib\media\image-618.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-618.png"></div><p></p></li><li data-line="10"><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297424922).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424922).png" style="max-width:100%"></div><p></p></li><li data-line="12"></li></ul></li></ul></li><li data-line="14"><p>Usually 4-6 months of cytoreductive therapy with novel agents (linedomide or proteasome inhibitor)</p><ul><li data-line="15"><p></p><div alt="6b2dacb57ccef288bec26372cfc90706" src="../_resources/6b2dacb57ccef288bec26372cfc90706" class="internal-embed is-loaded file-embed mod-empty-attachment">“../_resources/6b2dacb57ccef288bec26372cfc90706” could not be found.</div><p></p></li><li data-line="17"><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297425516).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425516).png" style="max-width:100%"></div><p></p></li></ul></li></ul></div><div><p>Dara does not seem to work well in high risk patients</p></div><div><p><strong>Tandem Transplant data</strong><br></p><div width="700" alt="image.png" src="lib\media\image-(1686297423615).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423615).png" style="max-width:100%"></div><p></p></div><div><p><strong>High Risk Cytogenetics Options</strong><br>**<br>**<br></p><div width="980" alt="image.png" src="lib\media\image-624.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-624.png" style="max-width:100%"></div><br>All treatments work less well<p></p></div><div><ul><li data-line="0"><p>Dara-VTD-ASCT</p></li><li data-line="1"><p>KRd-ASCT</p></li><li data-line="2"><p>Tandem transplant: PFS benefit</p></li><li data-line="3"><p>Maintenance: two-agent maintenance, eg DR or VR</p><ul><li data-line="4"><p></p><div width="500" alt="image.png" src="lib\media\image-622.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-622.png" style="max-width:100%"></div><p></p></li><li data-line="6"></li></ul></li></ul></div><div><p>Ultra-high risk NDMM:</p></div><div><p></p><div alt="image.png" src="lib\media\image-621.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-621.png"></div><p></p></div><div><p>Phase 2 GMMG Concept Study: Isa KRD<br></p><div alt="image.png" src="lib\media\image-(1686297421170).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421170).png"></div><p></p></div><div><p>Phase 2 Master Study: Dara-KRD / ASCT / more consolidation<br></p><div alt="image.png" src="lib\media\image-(1686297425103).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425103).png"></div><p></p></div><div><p><strong>Monitoring Response</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-619.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-619.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297426756).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426756).png"></div><p></p></div><div><p>Used to track MRD for Plasma cells (all are aberrant markers)<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297424700).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424700).png" style="max-width:100%"></div><p></p></div><div><p><strong>Supportive</strong></p></div><div><ul><li data-line="0"><p>Bone Disease</p><ul><li data-line="1">Bisphosphonates for osteopenia or lytic bone lesions (renal dosed)<ul><li data-line="2">Pamidronate or Zoledronic Acid -&gt; zoledronic acid improves survival</li><li data-line="3">Denosumab</li><li data-line="4">Risk of osteonecrosis of the Jaw</li></ul></li><li data-line="5">Kyphoplasty/Vertebroplasty for vertebral fractuers</li><li data-line="6">Local XRT for bone pain</li></ul></li><li data-line="8"><p>Treat Hypercalcemia</p></li><li data-line="9"><p>Treat hypogammaglobulinemia</p></li><li data-line="10"><p>Prophylactic Abx</p><ul><li data-line="11">PJP on high dose steroids</li><li data-line="12">VZV on proteasome inhibitors</li><li data-line="13">Levofloxacin for at least 3 months</li></ul></li><li data-line="14"><p>EPO for anemia</p></li><li data-line="15"><p>DVT prophylaxis</p><ul><li data-line="16">No risk factors: ASA 81 mg</li><li data-line="17"><blockquote><p>2 risk factors = LMWH</p></blockquote></li><li data-line="18">LMWH if &gt; 2 risk factors</li><li data-line="19">Especially high for lenalidomide treated</li><li data-line="20"><div alt="image.png" src="lib\media\image-626.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-626.png"></div></li><li data-line="21">Risk factors</li><li data-line="22"><div alt="image.png" src="lib\media\image-625.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-625.png"></div></li></ul></li></ul></div><div><p><a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/484b3190-3053-ba8c-a046-62dcafe87d5e/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/484b3190-3053-ba8c-a046-62dcafe87d5e/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Multiple Myeloma: Relapsed</a></p></div></div></div></div></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Active Multiple Myeloma</div></div><div class="canvas-node" style="z-index:4;transform:translate(-760px,-220px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0;min-height:12690px"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> <span class="token string">'Multiple Myeloma: Relapsed Refractory'</span>
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-01-25 15:47:36Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-11-04 03:15:04Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>Relapsed Disease</strong><br>**<br>**</p></div><div><ul><li data-line="0">Generally has lower PFS, lower response rates</li><li data-line="1">Treatment Indications<ul><li data-line="2">Start treatment when CRAB/Clinical symptoms appear</li><li data-line="3">High risk (cytogenetics) disease with any progression</li><li data-line="4">Rapid Doubling of M spike/FLC</li><li data-line="5">Advanced relapse (2 or more lines of therapy)</li></ul></li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-217.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-217.png"></div><p></p></div><div><p><strong>Biology</strong></p></div><div><p>Relapse can be same clone, different clone, different chain, oligosecretory!</p></div><div><p>Clones ae always competing for survival and chemo may bring one out more than another</p></div><div><p>Emerging and regressing clones</p></div><div><p></p><div width="600" alt="image.png" src="lib\media\image-235.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-235.png" style="width:600px;max-width:100%"></div><p></p></div><div><p><strong>Criteria</strong><br></p><div width="514" alt="image.png" src="lib\media\image-236.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-236.png" style="width:514px;max-width:100%"></div><p></p></div><div><p><strong>Approach</strong></p></div><div><p><strong>Fork: Len refractory or not?</strong><br>**<br>**<br></p><div width="700" alt="image.png" src="lib\media\image-228.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-228.png" style="width:700px;max-width:100%"></div><p></p></div><div><p>see below:</p></div><div><p><strong>Len sensitive</strong></p></div><div><p></p><div width="650" alt="image.png" src="lib\media\image-233.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-233.png" style="width:650px;max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297428398).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297428398).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297429066).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297429066).png" style="width:500px;max-width:100%"></div><p></p></div><div><p><strong>Len Refractory</strong><br>**<br>**</p></div><div><p><em>Option Two: Use a carfilzomib backbone </em>+ monoclonal antibody (makes you triple refractory/exposed, making you eligible for bite/car-t)</p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297428031).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297428031).png" style="width:500px;max-width:100%"></div><p></p></div><div><p>Evidence<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297427365).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297427365).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297428875).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297428875).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297427183).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297427183).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297428652).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297428652).png" style="width:500px;max-width:100%"></div><p></p></div><div><p><em>Option two: Pomalidomide based regimen</em></p></div><div><ul><li data-line="0"></li><li data-line="1"><div width="500" alt="image.png" src="lib\media\image-(1686297428222).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297428222).png" style="width:500px;max-width:100%"></div></li></ul></div><div><p>Salvage Transplant</p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297429242).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297429242).png" style="width:500px;max-width:100%"></div><p></p></div><div><p><strong>When you fail all of the above...</strong></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297427850).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297427850).png" style="width:500px;max-width:100%"></div><p></p></div><div><p><strong>Selecting a Treatment Regimen</strong></p></div><div><ul><li data-line="0">Each relapse has a lower response rate, shorter PFS, higher risk of cumulative toxicities<ul><li data-line="1">Disease biology</li><li data-line="2">Treatments already tried</li><li data-line="3">Residual toxicities</li><li data-line="4">Available therapies</li></ul></li><li data-line="5">Transplant?<ul><li data-line="6">We don't do transplant beyond 1st relapse, as low rate of success</li></ul></li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297427629).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297427629).png"></div><p></p></div><div><p><strong>1st Relapse</strong></p></div><div><p>Principles</p></div><div><ul><li data-line="0"><p>Options are most influenced by what was given as first line.</p><ul><li data-line="1">If refractory/progressed on Len, don't give more Len</li></ul></li><li data-line="2"><p>May include salvage transplant for patients with good remission with the first.</p><ul><li data-line="3"><p>I.e. if first remission was &lt;42 months, second will be 20 months; if &gt;42 months, second will be 45 months</p><ul><li data-line="4"><p></p><div width="725" alt="image.png" src="lib\media\image-227.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-227.png" style="width:725px;max-width:100%"></div><p></p></li><li data-line="6"></li></ul></li></ul></li><li data-line="8"><p>Can consider either PI based therapy (e.g. KD, DVd, PVd all &gt; Vd)</p></li></ul></div><div><p><strong>or</strong> if they can have Lenalidomide, can do Rd backbone (KRd, IRd, DrD)</p></div><div><pre><code>- ![image.png](../_resources/image-220.png)
- ![image.png](../_resources/image-229.png)

-
</code><button class="copy-code-button">Copy</button></pre></div><div><p></p><div alt="image.png" src="lib\media\image-234.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-234.png"></div><p></p></div><div><p>K=Carfilzomib; Vd=bortezomib+dex; Rd=lenalidomide+dex; Pom=pomalidomide; HR=hazard ratio; PFS=progression free survival; OS=overall survival; ASCT=autologous stem cell transplant: PI=proteosome inhibitor</p></div><div><p>Note that Dara+Rd is superior if can use lenalidomide</p></div><div><p>Dara/Isatuximab (Anti-CD38) based options<br></p><div alt="image.png" src="lib\media\image-224.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-224.png"></div><p></p></div><div><p>Trial summary<br></p><div alt="image.png" src="lib\media\image-219.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-219.png"></div><p></p></div><div><p>Unique Population: Highly functional high risk MM</p></div><div><p>Allo-transplant vs. CART<br></p><div alt="image.png" src="lib\media\image-222.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-222.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-226.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-226.png"></div><div alt="image.png" src="lib\media\image-218.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-218.png"></div><p></p></div><div><p><strong>2nd Relapse</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-216.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-216.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-232.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-232.png"></div><br>Depends on what they were exposed to<br>Typically all with be len refractory<br>Options<p></p></div><div><ul><li data-line="0"><p>Pom based - Pd, PCd</p></li><li data-line="1"><p>Carfilzomib based - Kd, KCd</p></li><li data-line="2"><p>Dara based, Isatuximab based</p></li><li data-line="3"><p>Selenixor based = SPd</p><ul><li data-line="4">Typically patients refractory to several previous lines.</li><li data-line="5">RP2D: Selinexor 60 mg days 1, 8, 15, 22 + Pomalidomide 4 mg days 1-21 q28 days</li><li data-line="6">PFs not yet reached</li></ul></li><li data-line="7"><p>Belantamab</p><ul><li data-line="8"><p></p><div alt="image.png" src="lib\media\image-221.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-221.png"></div><p></p></li><li data-line="10"></li></ul></li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-238.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-238.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-225.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-225.png"></div><p></p></div><div><p>PFS Table for Treatments</p></div><div><p></p><div alt="image.png" src="lib\media\image-223.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-223.png"></div><p></p></div><div><p>Next...</p></div><div><ul><li data-line="0"><p>Consider BCMA</p></li><li data-line="1"><p>BITE</p><ul><li data-line="2"><p></p><div alt="image.png" src="lib\media\image-231.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-231.png"></div><p></p></li><li data-line="4"></li></ul></li><li data-line="6"><p>CAR-T Cell clinical trials</p><ul><li data-line="7"><div alt="image.png" src="lib\media\image-230.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-230.png"></div></li><li data-line="8"><div alt="image.png" src="lib\media\image-237.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-237.png"></div></li><li data-line="9">high risk by stage R-ISS don't do as well as high risk cytogenetics</li></ul></li><li data-line="11"><p>Cel-MoDs</p></li></ul></div><div><p>Elotuzumab, dratumumab, panobinostat, selinexor, belantamab</p></div><div><p><a class="internal-link is-unresolved" data-href="../_resources/Ottawa RRMM Oct 22 2021.pptx" href="../_resources/Ottawa RRMM Oct 22 2021.pptx" target="_self" rel="noopener">Ottawa RRMM Oct 22 2021.pptx</a></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Multiple Myeloma_ Relapsed Refractory</div></div><div class="canvas-node" style="z-index:5;transform:translate(-760px,240px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Multiple myeloma high risk
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2023-04-11 13:33:31Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-10-19 01:43:03Z</span>
<span class="token key atrule">author</span><span class="token punctuation">:</span> inna.gong@gmail.com</code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>Defining high risk disease at diagnosis&nbsp;</strong><br></p><div width="500" alt="../_resources/09066cbbe37d8fbc6bc4e3a3ec012318.png" src="lib\media\09066cbbe37d8fbc6bc4e3a3ec012318.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/09066cbbe37d8fbc6bc4e3a3ec012318.png" src="lib\media\09066cbbe37d8fbc6bc4e3a3ec012318.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/dbd2f62c3858e6abffff840cf9028d67.png" src="lib\media\dbd2f62c3858e6abffff840cf9028d67.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/dbd2f62c3858e6abffff840cf9028d67.png" src="lib\media\dbd2f62c3858e6abffff840cf9028d67.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/3b26071582611d2048cf996b84c0d132.png" src="lib\media\3b26071582611d2048cf996b84c0d132.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/3b26071582611d2048cf996b84c0d132.png" src="lib\media\3b26071582611d2048cf996b84c0d132.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Blind spots lead to unexpected frequent relapses in clinic because we’re not looking at disease biology in totality in a patient yet</li></ul></div><div><p>Treatment strategies over time</p></div><div><p>Depth of response seen with bortezomib; much less pronounced with thalidomide<br></p><div width="425" alt="../_resources/3824c23bff4a11c598d3ce33cc6a2ec4.png" src="lib\media\3824c23bff4a11c598d3ce33cc6a2ec4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/3824c23bff4a11c598d3ce33cc6a2ec4.png" src="lib\media\3824c23bff4a11c598d3ce33cc6a2ec4.png" style="max-width:100%"></div><br>At this point: PFS only 26 months in high risk patients<br><div width="450" alt="../_resources/641c20a0a110531af09be562d901bed6.png" src="lib\media\641c20a0a110531af09be562d901bed6.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/641c20a0a110531af09be562d901bed6.png" src="lib\media\641c20a0a110531af09be562d901bed6.png" style="max-width:100%"></div><p></p></div><div><p>SWOG 1211 schema - first RCT for high risk patients<br></p><div width="500" alt="../_resources/0d9ab1234af34c52e0ff5a05c656d3c5.png" src="lib\media\0d9ab1234af34c52e0ff5a05c656d3c5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/0d9ab1234af34c52e0ff5a05c656d3c5.png" src="lib\media\0d9ab1234af34c52e0ff5a05c656d3c5.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">High risk definition</li><li data-line="1"><div width="500" alt="../_resources/5e4f9e74390c9b9741ac5c36b38c0546.png" src="lib\media\5e4f9e74390c9b9741ac5c36b38c0546.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5e4f9e74390c9b9741ac5c36b38c0546.png" src="lib\media\5e4f9e74390c9b9741ac5c36b38c0546.png" style="max-width:100%"></div></li><li data-line="2">No difference in PFS or OS</li><li data-line="3"><div width="500" alt="../_resources/7955fbf3c323f1ea35cec02291c7e939.png" src="lib\media\7955fbf3c323f1ea35cec02291c7e939.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7955fbf3c323f1ea35cec02291c7e939.png" src="lib\media\7955fbf3c323f1ea35cec02291c7e939.png" style="max-width:100%"></div></li></ul></div><div><p>Emory experience: RvD induction, consolidation and maintenance<br></p><div width="500" alt="../_resources/ef5f5bb07f392ae7756d0912fcb53aa2.png" src="lib\media\ef5f5bb07f392ae7756d0912fcb53aa2.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ef5f5bb07f392ae7756d0912fcb53aa2.png" src="lib\media\ef5f5bb07f392ae7756d0912fcb53aa2.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">ISS 3: PFS 31 months</li></ul></div><div><p>Summary of high risk subsets in contemporary studies<br></p><div width="625" alt="../_resources/8429aa01147ed830231d89b57f7d4318.png" src="lib\media\8429aa01147ed830231d89b57f7d4318.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/8429aa01147ed830231d89b57f7d4318.png" src="lib\media\8429aa01147ed830231d89b57f7d4318.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">High risk definition not uniform across studies</li></ul></div><div><p>KRd for induction<br></p><div width="575" alt="../_resources/6be4ee50e3071f06096058dfb7506296.png" src="lib\media\6be4ee50e3071f06096058dfb7506296.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/6be4ee50e3071f06096058dfb7506296.png" src="lib\media\6be4ee50e3071f06096058dfb7506296.png" style="max-width:100%"></div><p></p></div><div><p>Treatment algorithm<br></p><div width="500" alt="../_resources/b39916a4b5b7e79b69bf55bb9ff07bfc.png" src="lib\media\b39916a4b5b7e79b69bf55bb9ff07bfc.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/b39916a4b5b7e79b69bf55bb9ff07bfc.png" src="lib\media\b39916a4b5b7e79b69bf55bb9ff07bfc.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="700" alt="../_resources/acafe11a6ed38a23650e327aeb865ffc.png" src="lib\media\acafe11a6ed38a23650e327aeb865ffc.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/acafe11a6ed38a23650e327aeb865ffc.png" src="lib\media\acafe11a6ed38a23650e327aeb865ffc.png" style="max-width:100%"></div><p></p></div><div><p>CAR-T therapy<br></p><div width="750" alt="../_resources/7d51d3d22d5c6e4a93d76463d82d4a48.png" src="lib\media\7d51d3d22d5c6e4a93d76463d82d4a48.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7d51d3d22d5c6e4a93d76463d82d4a48.png" src="lib\media\7d51d3d22d5c6e4a93d76463d82d4a48.png" style="max-width:100%"></div><p></p></div><div><p><strong>Tandem transplant</strong></p></div><div><p></p><div width="500" alt="../_resources/86479dfd9453ee770154125283c93fb5.png" src="lib\media\86479dfd9453ee770154125283c93fb5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/86479dfd9453ee770154125283c93fb5.png" src="lib\media\86479dfd9453ee770154125283c93fb5.png" style="max-width:100%"></div><br><div width="475" alt="../_resources/58eafbf084b15a75d89fb78a013e8c18.png" src="lib\media\58eafbf084b15a75d89fb78a013e8c18.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/58eafbf084b15a75d89fb78a013e8c18.png" src="lib\media\58eafbf084b15a75d89fb78a013e8c18.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/de61827a1f7fdcadeb5ed247adc0cb9c.png" src="lib\media\de61827a1f7fdcadeb5ed247adc0cb9c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/de61827a1f7fdcadeb5ed247adc0cb9c.png" src="lib\media\de61827a1f7fdcadeb5ed247adc0cb9c.png" style="max-width:100%"></div><p></p></div><div><p>Maintenance therapy:</p></div><div><ul><li data-line="0">Evidence for ixazomib comes from TOURMALINE trial: showed benefit with high risk cytogenetics, compared to placebo</li></ul></div><div><p></p><div width="725" alt="../_resources/7b7b38df7b46297ad48ce0ff7608462e.png" src="lib\media\7b7b38df7b46297ad48ce0ff7608462e.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7b7b38df7b46297ad48ce0ff7608462e.png" src="lib\media\7b7b38df7b46297ad48ce0ff7608462e.png" style="max-width:100%"></div><br><div width="700" alt="../_resources/e9970ee0d949a1bedc92a542e6bd2d5d.png" src="lib\media\e9970ee0d949a1bedc92a542e6bd2d5d.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e9970ee0d949a1bedc92a542e6bd2d5d.png" src="lib\media\e9970ee0d949a1bedc92a542e6bd2d5d.png" style="max-width:100%"></div><p></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Multiple myeloma high risk</div></div><div class="canvas-node" style="z-index:6;transform:translate(-1200px,-684px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Multiple myeloma staging<span class="token punctuation">,</span> myeloma cytogenetics<span class="token punctuation">,</span> high risk disease
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-06-18 16:58:32Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2022-05-04 19:31:28Z</span>
<span class="token key atrule">author</span><span class="token punctuation">:</span> inna.gong@gmail.com</code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>STAGING</strong><br><strong></strong></p><div src="lib\media\234fdf0926a21ccd636d09047b755844.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\234fdf0926a21ccd636d09047b755844.png"></div><br>**<br>**<br><strong><div src="lib\media\03206c361c684aab84d1a7aafa978ddb.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\03206c361c684aab84d1a7aafa978ddb.png"></div></strong><br>**<br>**<br><strong>CYTOGENETICS</strong><p></p></div><div><p></p><div src="lib\media\e2a5129b6d4cd6972bcf058eb9023278.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\e2a5129b6d4cd6972bcf058eb9023278.png"></div><p></p></div><div><p>Prognosis<br></p><div src="lib\media\c4c4d46d9e99a6d186c11d316a5c91f0.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c4c4d46d9e99a6d186c11d316a5c91f0.png"></div><p></p></div><div><p></p><div src="lib\media\fc12761697e6faf0bf4aeb5bd0b573b5.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\fc12761697e6faf0bf4aeb5bd0b573b5.png"></div><p></p></div><div><p></p><div src="lib\media\41c809810df5298748a94ab3651a7b69.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\41c809810df5298748a94ab3651a7b69.png"></div><br><div src="lib\media\92395973474ea40f31a5da8ecbbb0fea.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\92395973474ea40f31a5da8ecbbb0fea.png"></div><p></p></div><div><p></p><div src="lib\media\c0e7734e81f2282ff8529f9a03b24dfe.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c0e7734e81f2282ff8529f9a03b24dfe.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-390.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-390.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-377.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-377.png"></div><p></p></div><div><p>Molecular characteristics matter, same translocation can be standard or high risk!</p></div><div><p></p><div alt="image.png" src="lib\media\image-388.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-388.png"></div><p></p></div><div><ul><li data-line="0">1q: considered high risk if in conjunction with high ISS, 2 or more cytogenetics abnormalities<ul><li data-line="1">Gain 1q: 3 copies</li><li data-line="2">Amplification: 4 copies</li><li data-line="3">Now incorporated into second revision ISS</li></ul></li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297228314).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297228314).png"></div><p></p></div><div><p>High risk<br>t(4;14)</p></div><div><ul><li data-line="0">dysregulation of two genes on chromosome 4, the fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET), together with the formation of IGH/MMSET hybrid transcripts</li></ul></div><div><p>t(14;16)</p></div><div><ul><li data-line="0">rearrangement of the MAF gene, which encodes a transcription factor binding to CCND2</li></ul></div><div><p>t(14;20)</p></div><div><p>Standard risk<br>t(11;14)</p></div><div><ul><li data-line="0">juxtaposition of the IgH locus on chromo- some 14 to the oncogene cyclin D1 (CCND1) on chro- mosome 11, leading to the overexpression of CCND1 in plasma cells</li><li data-line="1">genetically stable with a low rate of subclone formation and progression</li><li data-line="2">associated with low plasma cell clones in the bone marrow, but they tend to be loaded with a heavy FLC burden in the serum</li></ul></div><div><p>Patients with gain 1q alone (1/3 of all newly diagnosed myeloma patients) without other cytogenetic abnormalities are intermediate risk: single transplant without tandem</p></div><div><ul><li data-line="0">Unless they are ISS stage 3 at diagnosis: high risk with gain 1q</li><li data-line="1">Tandem transplant over sequential transplant in studies only better for high risk patients with combination cytogenetics</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-385.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-385.png"></div><br><div alt="image.png" src="lib\media\image-391.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-391.png"></div><br><strong>Defining high risk disease at diagnosis&nbsp;</strong><br><div src="lib\media\09066cbbe37d8fbc6bc4e3a3ec012318.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\09066cbbe37d8fbc6bc4e3a3ec012318.png"></div><p></p></div><div><p></p><div src="lib\media\dbd2f62c3858e6abffff840cf9028d67.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\dbd2f62c3858e6abffff840cf9028d67.png"></div><br><div src="lib\media\3b26071582611d2048cf996b84c0d132.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\3b26071582611d2048cf996b84c0d132.png"></div><p></p></div><div><ul><li data-line="0">Blind spots lead to unexpected frequent relapses in clinic because we’re not looking at disease biology in totality in a patient yet</li></ul></div><div><p>Can relapse with <strong>different </strong>cyogenetics</p></div><div><p></p><div alt="image.png" src="lib\media\image-387.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-387.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-374.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-374.png"></div><div alt="image.png" src="lib\media\image-386.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-386.png"></div><p></p></div><div><p>6% are '<strong>double hit</strong>', with 1q amplification and tp53 mutations</p></div><div><p><strong>Prognosis</strong></p></div><div><p></p><div src="lib\media\da5688a705a577fc4082784b7d38600d.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\da5688a705a577fc4082784b7d38600d.png"></div><p></p></div><div><p></p><div src="lib\media\c3f86f3619593fc696c7f02db9be132d.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c3f86f3619593fc696c7f02db9be132d.png"></div><p></p></div><div><p>R2-ISS</p></div><div><ul><li data-line="0">ISS stage II (1 point), ISS stage III (1.5 points), del(17p) (1 point), high lactate dehydrogenase (1 point), t(4;14) (1 point), and 1q copy number alterations (0.5 point)</li></ul></div><div><p></p><div src="lib\media\e70c1942085d57441990454993529ffe.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\e70c1942085d57441990454993529ffe.png"></div><p></p></div><div><p></p><div src="lib\media\55fc88cec7d62609f5238b1fe95b50a5.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\55fc88cec7d62609f5238b1fe95b50a5.png"></div><p></p></div><div><p><strong>TRIAL In high risk disease</strong></p></div><div><p>Transplant eligible</p></div><div><p></p><div src="lib\media\770c72c4af792173b067f03c84e1dbed.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\770c72c4af792173b067f03c84e1dbed.png"></div><p></p></div><div><p>Transplant ineligible<br></p><div src="lib\media\0eb929ae670058baaf1ed054bbc4f0da.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\0eb929ae670058baaf1ed054bbc4f0da.png"></div><p></p></div><div><p>Relapsed refractory high risk</p></div><div><p></p><div src="lib\media\b3be77e521d708ab47038f3dad16aea1.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\b3be77e521d708ab47038f3dad16aea1.png"></div><p></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Multiple myeloma staging, myeloma cytogenetics, hi</div></div><div class="canvas-node" style="z-index:7;transform:translate(-1637px,-220px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Smoldering multiple myeloma
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-08-25 21:34:19Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-09-12 17:18:07Z</span>
<span class="token key atrule">author</span><span class="token punctuation">:</span> inna.gong@gmail.com</code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>Epidemiology</strong></p></div><div><p></p><div src="lib\media\e571c8c7f6f691f8a314ddd5b9e9a408.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\e571c8c7f6f691f8a314ddd5b9e9a408.png"></div><p></p></div><div><ul><li data-line="0">Blacks have higher prevalence of MGUS and higher progression</li></ul></div><div><p>*<strong>*Definition</strong>:&nbsp;**Myeloma without end organ damage (including amyloidosis) and BM plasma cells &lt; 60%</p></div><div><p></p><div src="lib\media\df8531ad9babd028e48796f56cf9ceba.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\df8531ad9babd028e48796f56cf9ceba.png"></div><br><div src="lib\media\edf60c276262a78f2f72a6aaf1792b45.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\edf60c276262a78f2f72a6aaf1792b45.png"></div><p></p></div><div><p><strong>Pathophysiology</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297132371).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297132371).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297132971).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297132971).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297132668).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297132668).png"></div><p></p></div><div><p><strong>Clonal evolution</strong></p></div><div><p></p><div src="lib\media\a282e82b5748ebdf957de4cd831fbe05.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\a282e82b5748ebdf957de4cd831fbe05.png"></div><p></p></div><div><ul><li data-line="0">Branching pattern: multiple clones that develop branching mutations<ul><li data-line="1">Slower progression</li></ul></li><li data-line="2">Stable: all the changes required for MM is already present until replication reaches threshold for myeloma<ul><li data-line="3">Shorter time to progression from MGUS to MM</li></ul></li></ul></div><div><p><strong>Risk stratification&nbsp;</strong></p></div><div><p><strong>Risk stratification</strong></p></div><div><p></p><div src="lib\media\b59411c2055c1734728846a31613774b.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\b59411c2055c1734728846a31613774b.png"></div><br><strong>History of risk stratification</strong><br><div src="lib\media\4409d8655446daddc6e1c7cd6ead5f2e.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\4409d8655446daddc6e1c7cd6ead5f2e.png"></div><p></p></div><div><ul><li data-line="0">Mayo 20/20/2 score has been validated independently</li><li data-line="1">IMWG score 2020 includes FISH cytogenetics information</li></ul></div><div><p></p><div src="lib\media\9589b2de002eee0f455597176d8e769a.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\9589b2de002eee0f455597176d8e769a.png"></div><p></p></div><div><p></p><div src="lib\media\94f7dfa9a863a1e2a7a9b3b8449d98a6.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\94f7dfa9a863a1e2a7a9b3b8449d98a6.png"></div><p></p></div><div><p></p><div src="lib\media\692acd353159c262ddb40ca2d0617e77.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\692acd353159c262ddb40ca2d0617e77.png"></div><p></p></div><div><p>20-20-20 risk for progression: 3 factor model</p></div><div><ul><li data-line="0">BM PC &gt; 20%</li><li data-line="1">M Spike &gt; 20 g/L</li><li data-line="2">FLC ratio &gt; 20</li><li data-line="3">Cytogenetics: t(4;14), t(14;16), +1q, del13q/monosomy 13</li><li data-line="4">Risk of progression at 5 years<ul><li data-line="5">0 risk factors: 25%,</li><li data-line="6">1 risk factor: 50%</li><li data-line="7">2+ risk factors: 75%</li><li data-line="8">After 5 years: risk about 20% for 5-10 years; after 10 years: MGUS risk 1%/year</li></ul></li></ul></div><div><p>4-factor model<br></p><div src="lib\media\e3e8d482aecaa5c24b52d4658b4681fc.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\e3e8d482aecaa5c24b52d4658b4681fc.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297132035).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297132035).png"></div><br>Monitoring: q2-3 months for first few years; once reach 5 years, follow q1year<p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297131548).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297131548).png"></div><p></p></div><div><p>10% per year risk, highest risk in first 5 years but after that they are likely more like MGUS</p></div><div><p></p><div src="lib\media\5cabf6e28acf9a71ca61b28dae81c453.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\5cabf6e28acf9a71ca61b28dae81c453.png"></div><br><div src="lib\media\ee84c9b30c73cbed6835b0f5ecf184cf.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\ee84c9b30c73cbed6835b0f5ecf184cf.png"></div><p></p></div><div><ul><li data-line="0"><strong>Mayo risk stratification: M spike &gt; 20, BM &gt;20%, FLC ratio &gt; 20</strong></li><li data-line="1">2 risk factor = high risk<ul><li data-line="2">25% risk of progression in 2 years; 2 years median progression</li><li data-line="3">1/3 of all Smoldering MM: time to progression of 2 years to MM (50% risk progression at 2 years; studies support Len-dex improve risk of progression by 90%; does not impact future OS)</li></ul></li><li data-line="4">1 risk factor = intermediate risk</li><li data-line="5">0 = low risk</li><li data-line="6">High risk: 4;14; dell17p; 1q gain</li></ul></div><div><p><strong>IMWG scoring system&nbsp;</strong><br></p><div src="lib\media\b07e7008bac78183bf3e1b9520af2422.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\b07e7008bac78183bf3e1b9520af2422.png"></div><p></p></div><div><ul><li data-line="0">The risk stratification was validated by IMWG</li><li data-line="1"><strong>High risk = risk of progression 50%</strong></li></ul></div><div><p></p><div src="lib\media\700c3ead2ffdffb4dc76ab8a21668080.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\700c3ead2ffdffb4dc76ab8a21668080.png"></div><br>Interval change is also important<p></p></div><div><ul><li data-line="0">For low risk patients: M spike &gt; 0.5 g, Hgb falls by 5 —&gt; high risk of progression</li></ul></div><div><p><strong>Sample cases&nbsp;</strong></p></div><div><p>This is case of MM<br></p><div src="lib\media\f43a01748d69d9540a7a1c7b88facb66.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\f43a01748d69d9540a7a1c7b88facb66.png"></div><br><div src="lib\media\86be72e85e6517dbdcf99834ad50ad91.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\86be72e85e6517dbdcf99834ad50ad91.png"></div><p></p></div><div><ul><li data-line="0">Smoldering MM: poor prognosis</li><li data-line="1">Last 10 years: smoldering MM heterogeneous disease, not just in between MGUS and MM<ul><li data-line="2">50% have MGUS</li><li data-line="3">50% MM</li></ul></li><li data-line="4">IMWG: need to discern those patients with smoldering who really have MM, hence biomarkers defined to identify MM using MM-defining events<ul><li data-line="5">However this only upstages 15% of patients, we still need to define how to identify high risk SMM vs low risk SMM</li><li data-line="6">Need to identify high risk SMM patients because they’re more likely to progress in first 3-5 years, thereafter curve plateaus similar to progression similar to MGUS progression (See graph above)</li></ul></li></ul></div><div><p></p><div src="lib\media\72593361c1d953d65822013f57d3c27e.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\72593361c1d953d65822013f57d3c27e.png"></div><br><div src="lib\media\71cb974083102fa0fb6a84d64c02306f.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\71cb974083102fa0fb6a84d64c02306f.png"></div><br><div src="lib\media\c8904fd6386a8d1015ea380bdaff6bd9.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c8904fd6386a8d1015ea380bdaff6bd9.png"></div><p></p></div><div><p><strong>Treatment of high risk SMM</strong></p></div><div><p><strong></strong></p><div src="lib\media\58afd6b13c455a7a6281e8cbcac97a18.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\58afd6b13c455a7a6281e8cbcac97a18.png"></div><strong><br></strong><p></p></div><div><p><strong>Evidence</strong></p></div><div><p></p><div src="lib\media\ff41c9af1e3ff61079f3f17513ce3fe1.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\ff41c9af1e3ff61079f3f17513ce3fe1.png"></div><p></p></div><div><ul><li data-line="0">This was done prior to SLIM crab criteria: may have included some MM patients that made the difference</li></ul></div><div><p></p><div src="lib\media\38a4940669c7a34ae6c3546c13ecc1dc.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\38a4940669c7a34ae6c3546c13ecc1dc.png"></div><p></p></div><div><p>Results highlighted we need better biomarkers<br></p><div src="lib\media\c8e38d20e87b8cf730dffbcc7efd9f13.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c8e38d20e87b8cf730dffbcc7efd9f13.png"></div><p></p></div><div><p></p><div src="lib\media\10958394be693dad3d846da6b726d9b2.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\10958394be693dad3d846da6b726d9b2.png"></div><p></p></div><div><ul><li data-line="0">Reduced risk of development of CRAB features</li></ul></div><div><p></p><div src="lib\media\5e5612cf45df4bd491fa63e3ec923614.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\5e5612cf45df4bd491fa63e3ec923614.png"></div><p></p></div><div><ul><li data-line="0">Confirmed with ECOG study</li></ul></div><div><p></p><div src="lib\media\c309a9b832a9069234711579bb4822d4.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c309a9b832a9069234711579bb4822d4.png"></div><p></p></div><div><ul><li data-line="0">High risk: lenalidomide or len + dexamethasone (off label) OR clinical trial</li><li data-line="1">Unresolved questions to be answered: daratumumab, treat as MM?</li><li data-line="2">Duration: 2 years then stop and monitor</li></ul></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Smoldering multiple myeloma</div></div><div class="canvas-node" style="z-index:8;transform:translate(-1637px,-684px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> MGUS <span class="token punctuation">-</span> Monoclonal Gammopathy of Undetermined Significance
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2023-04-20 14:02:16Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-07-12 23:13:33Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>Monoclonal Gammaopathy&nbsp;</strong></p></div><div><ul><li data-line="0">Asymptomatic</li><li data-line="1">1% per year transforms to MM</li></ul></div><div><p><strong>Non-IgM MGUS</strong><br></p><div alt="image.png" src="lib\media\image-204.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-204.png"></div><p></p></div><div><p><strong>For Amyloidosis</strong>: Can start with bone marrow biopsy for amyloidosis, fat pad biopsy. Do mass spec to confirm it's truly monoclonal (e.g. instead of alzheimer's, diabetes and peptides. Can</p></div><div><p></p><div alt="image.png" src="lib\media\image-208.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-208.png"></div><br>Don't need plasma cells to have MGUS<p></p></div><div><p><strong>Light Chain MGUS</strong><br></p><div alt="image.png" src="lib\media\image-203.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-203.png"></div><p></p></div><div><p>Diagnosis and Monitoring of MGUS</p></div><div><p></p><div alt="image.png" src="lib\media\image-205.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-205.png"></div><p></p></div><div><p><strong>MGUS Management</strong></p></div><div><ul><li data-line="0">M protein anything other than IgG</li><li data-line="1">FLC ratio outside of 0.25 - 1.65</li><li data-line="2">M protein &gt; 15&nbsp; (or &gt; 3 for CKD)</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-210.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-210.png"></div><p></p></div><div><p>If Any of these risk factors present, need further testing...</p></div><div><ul><li data-line="0">IgM -&gt; look for plasmacytoma/lymphadenopathy</li><li data-line="1">Light chains -&gt; look for amyloidosis in kidney and heart</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-211.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-211.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-212.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-212.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-207.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-207.png"></div><p></p></div><div><p>Responding to Abnormal Testing<br></p><div alt="image.png" src="lib\media\image-209.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-209.png"></div><p></p></div><div><p>IgM tends to be lymphoplasmacytic<br>Amyloidosis</p></div><div><p><strong>Risk of Progression</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-202.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-202.png"></div><div alt="image.png" src="lib\media\image-206.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-206.png"></div><p></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">MGUS - Monoclonal Gammopathy of Undetermined Signi</div></div><div class="canvas-node" style="z-index:9;transform:translate(-280px,-684px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Plasma Cell Leukemia
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-08-15 12:25:00Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-08-18 12:21:21Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>Definition</strong><br></p><div alt="image.png" src="lib\media\image-324.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-324.png"></div><p></p></div><div><ul><li data-line="0">20% circulating plasma cells/ total plasma cells &gt; 2x10^9/L</li><li data-line="1">De novo PCL</li><li data-line="2">Secondary PCL = following MM</li></ul></div><div><p><strong>Features</strong><br></p><div alt="image.png" src="lib\media\image-325.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-325.png"></div><p></p></div><div><p><strong>Comparison with Myeloma</strong></p></div><div><p>PCL vs MM</p></div><div><ul><li data-line="0">&lt; age</li><li data-line="1"><blockquote><p>CD20, &lt;CD56, = CD38/138</p></blockquote></li><li data-line="2"><blockquote><p>t(11;14), t(4;14), t(14;16)</p></blockquote></li><li data-line="3">TP53</li><li data-line="4">ISS III</li><li data-line="5">Light chain only</li><li data-line="6">Non secretory</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-326.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-326.png"></div><p></p></div><div><p><strong>Pathology</strong></p></div><div><p><strong>Histology</strong><br></p><div alt="image.png" src="lib\media\image-328.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-328.png"></div><p></p></div><div><p><strong>Cytogenetics</strong><br></p><div alt="image.png" src="lib\media\image-327.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-327.png"></div><p></p></div><div><p><strong>Management</strong></p></div><div><p>Need LP when blood clears</p></div><div><p></p><div alt="image.png" src="lib\media\image-323.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-323.png"></div><p></p></div><div><ul><li data-line="0">RVd -&gt; ASCT -&gt; RVd</li><li data-line="1">Intensive chemotherapy -&gt; ?auto/allo</li></ul></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Plasma cell leukemia</div></div><div class="canvas-node" style="z-index:10;transform:translate(160px,-684px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Monoclonal Gammopathy Disorders (Fellow)
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-01-25 14:46:32Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2017-07-23 04:32:59Z</span>
<span class="token key atrule">source</span><span class="token punctuation">:</span> <span class="token punctuation">&gt;</span><span class="token punctuation">-</span>
  http<span class="token punctuation">:</span>//www.managingmyeloma.com/knowledge<span class="token punctuation">-</span>center/faq<span class="token punctuation">-</span>library/895<span class="token punctuation">-</span>what<span class="token punctuation">-</span>is<span class="token punctuation">-</span>the<span class="token punctuation">-</span>difference<span class="token punctuation">-</span>between<span class="token punctuation">-</span>smoldering<span class="token punctuation">-</span>myeloma<span class="token punctuation">-</span>and<span class="token punctuation">-</span>multiple<span class="token punctuation">-</span>myeloma
<span class="token key atrule">author</span><span class="token punctuation">:</span> sheharyar.raza@gmail.com</code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>The Plasma Celll</strong><br>Found in low numbers 3-5% in BM<br></p><div alt="image.png" src="lib\media\image-(1686297438231).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297438231).png"></div><p></p></div><div><p>Arises in bone marrow from a B-cell precursor -&gt; Lymph node -&gt; antigen exposure and becomes lymphoblast -&gt; becomes short lived plasma cell OR goes into lymph node and undergoes hypermutation and then either becomes memory cell or becomes long lived plasma cell producing antibodies (IgG, IgM, IgA, IgE)</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297439665).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297439665).png"></div><p></p></div><div><p><strong>Plasma Cell Disorders</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297432642).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297432642).png"></div><div alt="image.png" src="lib\media\image-(1686297431840).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297431840).png"></div><p></p></div><div><p></p><div alt="PlasmaCellID1793Fig1.png" src="lib\media\plasmacellid1793fig1.png" class="internal-embed media-embed image-embed is-loaded"><img alt="PlasmaCellID1793Fig1.png" src="lib\media\plasmacellid1793fig1.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297435792).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297435792).png"></div><p></p></div><div><p><strong>Disease Definitions</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297435979).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297435979).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297437003).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297437003).png"></div><p></p></div><div><p><strong>Pathophysiology</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297433129).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297433129).png"></div><p></p></div><div><p>MGUS &lt; 10% plasma cells<br>Myeloma &gt;10% plasma cells</p></div><div><p>Molecular Progression<br></p><div alt="image.png" src="lib\media\image-(1686297438420).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297438420).png"></div><p></p></div><div><p><strong>Etiology</strong></p></div><div><ul><li data-line="0"><p></p><div alt="image.png" src="lib\media\image-(1686297437608).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297437608).png"></div><p></p></li><li data-line="2"></li><li data-line="4"><p>IgH translocations in B-cells in germinal center</p></li><li data-line="5"><p></p><div alt="image.png" src="lib\media\image-(1686297432474).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297432474).png"></div><p></p></li><li data-line="6"><p>Cyclin D dysregulation -&gt; clonal plasma cell proliferation</p></li><li data-line="7"><p>More mutations are accumulated such as NFkB, leading to smoldering meloma state</p></li><li data-line="8"><p>More mutations in MYC, TP53, Rb, lead to myeloma</p></li></ul></div><div><p><strong>Pathology</strong></p></div><div><p><strong>Histology</strong></p></div><div><ul><li data-line="0">large pale blue cytoplasm</li><li data-line="1">central migration</li><li data-line="2">perinuclear clearing</li><li data-line="3">multiple-nuclei in cells</li><li data-line="4">dutcher bodies = cytoplasmic inclusions of immunoglobulins</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297433782).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297433782).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297438661).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297438661).png"></div><p></p></div><div><p><strong>Monoclonality</strong></p></div><div><ul><li data-line="0">1-2% of adults &gt; 50; 4-5% adults over 70 will have monoclonal gammopathy if looked for</li><li data-line="1">Monoclonality also presents in<ul><li data-line="2">Autoimmune disease</li><li data-line="3">Chronic inflammation</li><li data-line="4">MGUS</li><li data-line="5">Neoplasms</li></ul></li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297439424).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297439424).png"></div><p></p></div><div><p><strong>Reactive vs. Neoplastic Proliferations</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297436817).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297436817).png"></div><p></p></div><div><p><strong>Establish clonality</strong></p></div><div><ul><li data-line="0">light chain restriction</li><li data-line="1">Immunologic abberancy (loss of normal markers, gain of abnormal markers)</li><li data-line="2">plasma cell % (esp in biopsy rather than aspirate) -- flow not good for that</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297436592).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297436592).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297435119).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297435119).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-382.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-382.png"></div><p></p></div><div><p><strong>Morphology</strong><br>**<br>**<br>Lymphoplasmacytic myeloma can mimic lymphoma, and has different translocations</p></div><div><ul><li data-line="0">LPM has t 11;14 and IGH?-CCND1 translocation and CD20 expression</li><li data-line="1">LPL has MYD88</li></ul></div><div><p>Plasmamablastic myeloma</p></div><div><ul><li data-line="0">aggressive</li></ul></div><div><p>Anaplastic myeloma</p></div><div><ul><li data-line="0">difficult to recognize</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297438030).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297438030).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297433546).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297433546).png"></div><p></p></div><div><p>plasma vs. nucleated precursors, plasma cells: bigger, halo, nuclei are eccentric, bluer cytoplasm</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297432077).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297432077).png"></div><p></p></div><div><p>left to right: crystal, dutcher body, russel body</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297434771).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297434771).png"></div><br>mott cell<p></p></div><div><p><strong>Immunophenotype</strong><br>**<br>**<br></p><div alt="image.png" src="lib\media\image-383.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-383.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297439235).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297439235).png"></div><p></p></div><div><p><strong>IHC</strong><br></p><div alt="image.png" src="lib\media\image-376.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-376.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297434150).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297434150).png"></div><p></p></div><div><p><strong>FISH Cytogenetics</strong></p></div><div><p>First, separate out plasma cells using beads (need at least &gt;10% to do the test)</p></div><div><p></p><div alt="image.png" src="lib\media\image-380.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-380.png"></div><br>Need at least 10% of cells to demonstrate that genetic change<br><div alt="image.png" src="lib\media\image-375.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-375.png"></div><p></p></div><div><p>FISH probes look for different things<br></p><div alt="image.png" src="lib\media\image-379.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-379.png"></div><p></p></div><div><p>Typically start with IgH probe only, if positive then look for breakages/rearrangements</p></div><div><p>Only looks for certain break points<br></p><div alt="image.png" src="lib\media\image-384.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-384.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-381.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-381.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-378.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-378.png"></div><p></p></div><div><p><strong>Initial Investigations</strong><br>**<br>**</p></div><div><ul><li data-line="0"><p><strong>CBC</strong></p><ul><li data-line="1">Cytopenias (anemia)</li><li data-line="2">Rouleaux formation</li></ul></li><li data-line="4"><p><strong>Pre-treatment work-up</strong></p><ul><li data-line="5">TB, HIV, Hep B</li></ul></li><li data-line="7"><p><strong>Biochemistry&nbsp;</strong></p><ul><li data-line="8">Increased Ca+, Cr (CRAB)</li><li data-line="9">Quantitative immunoglobulins</li><li data-line="10">BNP for amyloidosis</li><li data-line="11">B2-microglobulin, albumin, LDH and CRP are poor prognosticators</li><li data-line="12">Proteinuria</li><li data-line="13">Urine <em>Bence Jones</em> Protein</li><li data-line="14">Decreased anion gap</li></ul></li><li data-line="16"><p><strong>Monoclonal proteins</strong></p><ul><li data-line="17">SPEP: spike in serum in 80%</li><li data-line="18">UPEP: demonstrates light chains in urine (15% only have this)<ul><li data-line="19">UPEP and Urine Immunofixation – 24 hour urine collecton – similar concepts as above.&nbsp;&nbsp;&nbsp;Main reason to do this is that it picks up many patients who have light chain secretion only, as those are rapidly excreted in the urine and thus are often not picked up on SPEP.</li></ul></li><li data-line="20">Serum Immunofixation – always done with SPEP, uses monospecific Abs for heavy and light chains – increases sensitivity to pick up M-protein and&nbsp;determines clonality (monoclonal vs polyclonal). Unlike SPEP, does not give quantitative estimate.</li><li data-line="21">Serum free light chain quantification: kappa and lambda</li></ul></li><li data-line="23"><p><strong>Bone marrow aspirate and biopsy</strong></p><ul><li data-line="24"><blockquote><p>10% plasma cells with abnormal morphology</p></blockquote></li><li data-line="25">Send for FISH or cytogenetics</li></ul></li><li data-line="27"><p><strong>Skeletal series (CT &gt; MRI &gt; X-Ray)</strong></p><ul><li data-line="28">Lytic lesions, sclerotic lesions</li><li data-line="29">Bone scans not useful since they detect osteoblast activity</li></ul></li></ul></div><div><p><strong>Imaging</strong><br>**<br>**</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297437355).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297437355).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297432795).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297432795).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297433975).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297433975).png"></div><p></p></div><div><p><strong>Electrophoresis</strong><br>**<br>**<br><strong>Immunoglobulins in myeloma...</strong></p></div><div><ul><li data-line="0">Can be Heavy chain (IgG &gt;&nbsp; IgA &gt; IgD &gt; IgM 0.5%)</li><li data-line="1">Can be Light chain (kappa, lambda)<ul><li data-line="2">The rapid turnover of FLC (2-6 hours) as compared with IgG (23 days) and other immunoglobulins (ie, Ig: 5.8 days; IgM: 5.1 days; IgD: 2.8 days; IgE: 2.3 days) contribute to FLC lability and thus make it a useful disease burden monitoring tool</li></ul></li><li data-line="3">Can be Heavy + light chain (excess light chains)</li><li data-line="4">Can be Light chain only</li><li data-line="5">Can be heavy chain only</li><li data-line="6">Can secrete nothing..! &lt;5%</li></ul></div><div><p>**<br>**<br><strong>Pearls</strong></p></div><div><ul><li data-line="0">Electrophoresis can distinguish large M-peaks (monoclonal protein)</li><li data-line="1">Some M-proteins can hide under other bands. E.g. IgD can often migrate with Beta instead of Gamma, and needs to be followed by IFE instead and Immunoglobulin levels</li><li data-line="2">Free light chains can be followed in serum, or in urine via bence jones protein</li></ul></div><div><p></p><div alt="61077da575a56acf029395ab75cc1f8a" src="lib\media\61077da575a56acf029395ab75cc1f8a.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="61077da575a56acf029395ab75cc1f8a" src="lib\media\61077da575a56acf029395ab75cc1f8a.jpg"></div><p></p></div><div><p>Patterns<br>**<br>**<br>**<br>**</p></div><div><ul><li data-line="0"><p></p><div alt="image.png" src="lib\media\image-(1686297436329).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297436329).png"></div><p></p></li><li data-line="2"><p></p><div alt="image.png" src="lib\media\image-(1686297434324).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297434324).png"></div><p></p></li><li data-line="3"><p><strong>Oligoclonal pattern </strong>is still potentially important if hiding a monoclonal protein, so wait for inflammation to die down</p></li><li data-line="4"><p></p><div alt="image.png" src="lib\media\image-(1686297437190).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297437190).png"></div><p></p></li><li data-line="6"></li><li data-line="8"><p><strong>Monoclonal pattern</strong></p></li><li data-line="9"><p></p><div alt="image.png" src="lib\media\image-(1686297432306).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297432306).png"></div><p></p></li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297438880).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297438880).png"></div><p></p></div><div><p><strong>Immunofixation</strong><br>**<br>**<br><strong>more sensitive and specific to antibodies</strong><br></p><div alt="image.png" src="lib\media\image-(1686297435314).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297435314).png"></div><p></p></div><div><p></p><div src="lib\media\c7e363642958dd29c504b1d669246edf.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c7e363642958dd29c504b1d669246edf.png"></div><p></p></div><div><p>M protein/ M spike = amount of antibody made by myeloma cell (proportion of total antibodies in the serum)</p></div><div><p></p><div src="lib\media\625be444ee0990941133a40c5671ee40.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\625be444ee0990941133a40c5671ee40.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297439057).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297439057).png"></div><p></p></div><div><p><strong>Free Light Chain</strong></p></div><div><p><strong>Normal Ratio</strong></p></div><div><p>As λ LCs are dimeric, their renal clearance is slower compared with κ LCs [Wochner et al. 1967], leading to a κ/λ ratio in the serum of about 0.58</p></div><div><p><strong>Ratio higher in CKD</strong></p></div><div><p>As the kidneys fail, however, the non-preferential reticulo-endothial route forms an increasing proportion of the FLC clearance</p></div><div><p>This results in a more similar serum half-life for the two FLCs and the FLC ratio therefore becomes increasingly influenced by the underlying production rates, by the plasma cells. There are approximately twice as many κ producing cells as there are λ cells and this results in a ratio of total κ to total λ in the serum of approximately 1.8</p></div><div><p>Kappa free light chains are thus higher in CKD, so ratio is 0.37-3.1 in CKD<br></p><div alt="image.png" src="lib\media\image-(1686297434549).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297434549).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297434946).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297434946).png"></div><p></p></div><div><p><strong>Urine Bence Jones</strong></p></div><div><p>Beyond a critical threshold, you pee out protein as bence jones protein</p></div><div><p>FLC serum test is pretty good, but much more expensive, compared to urinary bence jones</p></div><div><p>Uses urine test at diagnosis and work up to check for features of nephrotic syndrome, also to screen for nephrotic syndrome and establish a baseline albumin level</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297432960).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297432960).png"></div><p></p></div><div><p><strong>Quantitative Immunoglobulins</strong></p></div><div><ul><li data-line="0">Tested to diagnose concomittant hypogammaglobulinemia</li><li data-line="1">Useful for monitoring monoclonal proteins (eg. IgA) which migrate in the beta region of SPEP</li></ul></div><div><p><strong>Beta-2-Microglobulin</strong></p></div><div><ul><li data-line="0">B2M is a LMW protein synthesized by all nucleated cells present in all body fluids</li><li data-line="1">Shares similar structure to immunoglobulin molecules, makes beta-pleated sheets, associates with MHC-I molecules</li><li data-line="2">Causes dialysis related amyloidosis</li><li data-line="3">Levels correlate with tumor burden in myeloma and fall in response to therapy</li></ul></div><div><p><strong>Marrow When?</strong></p></div><div><p>Change in M protein level rapidly<br>Non IgG</p></div><div><p><strong>Bone Marrow</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297426529).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426529).png"></div><div alt="image.png" src="lib\media\image-(1686297433292).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297433292).png"></div><p></p></div><div><p><strong>Skeletal Imaging when?</strong></p></div><div><p><strong>Has to be CT or MRI</strong></p></div><div><p>WM does not have skeletal manifestations, so don't typically need skeletal imaging</p></div><div><p>Other types of Ig Isotype MGUS do need skeletal imaging</p></div><div><p><strong>Spectrum of Diseases</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297435567).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297435567).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297436163).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297436163).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297437840).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297437840).png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297431673).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297431673).png"></div><p></p></div><div><p>Natural History</p></div><div><p><strong><a href="#1a" class="tag" target="_blank" rel="noopener">#1a</a> Monoclonal Gammopathy of Undetermined Significance&nbsp;</strong></p></div><div><p>Read more here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/1a1cc2c4-2e13-d69e-4ee9-582c811c11cb/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/1a1cc2c4-2e13-d69e-4ee9-582c811c11cb/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">MGUS - Monoclonal Gammopathy of Undetermined Significance</a></p></div><div><p><strong><a href="#1b" class="tag" target="_blank" rel="noopener">#1b</a> Monoclonal Gammopathy of Renal Significance&nbsp; (MGRS)</strong></p></div><div><p>Umbrella term for pathologic renal damage related to monoclonal protein</p></div><div><p>Pathological renal damage</p></div><div><ul><li data-line="0">Amyloidosis</li><li data-line="1">Renal structures</li><li data-line="2">Cryoglobulin</li><li data-line="3">POEMS</li></ul></div><div><p><strong>#2 Smoldering Myeloma</strong><br>**<br>**</p></div><div><p>Full article here: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/73fc0c0e-e39f-a166-f010-557a04e2f1f5/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/73fc0c0e-e39f-a166-f010-557a04e2f1f5/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Smoldering Myeloma</a></p></div><div><p>Myeloma without end organ damage and BM plasma cells &lt; 60%</p></div><div><p>20-20-20 risk for progression</p></div><div><ul><li data-line="0">BM PC &gt; 20%</li><li data-line="1">M Spike &gt; 20 g</li><li data-line="2">FLC ratio &gt; 20</li><li data-line="3">Risk of progression is 25%, 50%, 75% at 5 years for 0, 1, 2+ risk factors</li></ul></div><div><p><strong>#3 Active Multiple Myeloma&nbsp;</strong></p></div><div><p>Full article here: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/fb2367a3-8bcf-02b5-b586-84cb215f7b6d/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/fb2367a3-8bcf-02b5-b586-84cb215f7b6d/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Active Multiple Myeloma</a></p></div><div><p><strong>#4 Plasmacytoma</strong><br>**<br>**</p></div><div><p>Full article here: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/71332930-cf8d-1524-ebd6-40dc249c6953/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/71332930-cf8d-1524-ebd6-40dc249c6953/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Plasmacytoma</a></p></div><div><p><strong>#5 Walderstrom Macroglobulinemia&nbsp;</strong><br><strong>(Lymphoplasmacytic Lymphoma)</strong></p></div><div><p>Full article here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/3aea3a19-b71e-ba0c-9168-6fdbc7087175/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/3aea3a19-b71e-ba0c-9168-6fdbc7087175/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Walderstrom Macroglobulinemia&nbsp;(Lymphoplasmacytic Lymphoma)</a></p></div><div><p><strong>#5 Primary Amyloidosis</strong></p></div><div><p>Full article here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/47b1680f-af0c-409b-805a-d81e7b3cf3dd/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/47b1680f-af0c-409b-805a-d81e7b3cf3dd/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">AL Amyloidosis</a></p></div><div><p><strong>#6 Plasma Cell Leukemia</strong></p></div><div><p>Full article here <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/4b88f943-f176-29bf-434d-fea87814a8d5/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/4b88f943-f176-29bf-434d-fea87814a8d5/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Plasma Cell Leukemia</a></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Monoclonal Gammopathy Disorders (Fellow)</div></div><div class="canvas-node" style="z-index:11;transform:translate(-280px,-220px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0;min-height:1151px"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Plasmacytoma
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2023-04-18 00:03:35Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-07-12 23:17:39Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p><strong>Definition</strong><br>**<br>**<br>Tumor made of clonal plasma cells<br></p><div alt="image.png" src="lib\media\image-249.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-249.png"></div><p></p></div><div><p><strong>Classification</strong></p></div><div><ul><li data-line="0">Solitary<ul><li data-line="1">Medullar (bone cavity)</li><li data-line="2">Extra-medullary</li></ul></li><li data-line="3">Multiple lesions = myeloma</li><li data-line="4">In conjunction with myeloma</li></ul></div><div><p><strong>Epi</strong></p></div><div><ul><li data-line="0">Bone plasmacytoma: 50% progress to MM</li><li data-line="1">Extramedullary plasmacytoma: 30% progress to MM</li></ul></div><div><p><strong>Investigations</strong></p></div><div><ul><li data-line="0">Work-up for myeloma</li><li data-line="1">Flow cytometry for clonal plasma cells</li><li data-line="2"><em>PET CT Scan</em></li><li data-line="3"><div alt="image.png" src="lib\media\image-248.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-248.png"></div></li></ul></div><div><p><strong>Treatment Algorithm</strong></p></div><div><p>I</p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">Plasmacytoma</div></div><div class="canvas-node" style="z-index:12;transform:translate(160px,-220px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0;min-height:3365px"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> POEMS Syndrome
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-06-18 20:51:07Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2016-03-09 12:08:59Z</span>
<span class="token key atrule">author</span><span class="token punctuation">:</span> wheels2540</code><button class="copy-code-button">Copy</button></pre></div><div><p><strong></strong></p><div src="lib\media\d9e94186f41fb4694a6a10d86299b63b.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\d9e94186f41fb4694a6a10d86299b63b.png"></div><strong><br></strong><br><strong><div src="lib\media\3e2817f9d685d62ef6b6419431a8072e.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\3e2817f9d685d62ef6b6419431a8072e.png"></div></strong><p></p></div><div><p><strong>POEMS:&nbsp;</strong>Also remember that POEMS is a very, very rare entity. In terms of monoclonal gammopathies, MGUS and multiple myeloma are by far the most common.</p></div><div><p><strong>P</strong>olyneuropathy (often many nerves involved; characteristically progressive weakness in legs and arms): diffferential demyelinating neuropathy vs. CIDP</p></div><div><p><strong>O</strong>rganomegaly (esp HSM),<br><strong>E</strong>ndocrinopathy,<br><strong>M</strong>-spike,</p></div><div><p><strong>S</strong>kin abnormalities (hyperpigmentation, hypertricosis, sclerosis). Characteristically has a very high VEGF level.</p></div><div><p><strong>Associated with high VEGF levels peripherally</strong></p></div><div><ul><li data-line="0">A very rare multisystem disorder, associated with monoclonal gammopathies or plasma cell dyscrasias</li><li data-line="1">Epi: M&gt;F, 40-50s</li><li data-line="2">Median time for onset of sx to dx = 13-18 mos!!</li><li data-line="3">DDx often includes: CIDP, primary amyloidosis, cryoglobulinemia, multiple myeloma (polyneuropathy is uncommon unless also with amyloid)</li><li data-line="4">Associatied disorders: Castleman’s disease, osteosclerotic myeloma</li><li data-line="5">Tx: two-pronged: 1) treat the underlying plasma cell disorder, 2) treat associated abnormalities/sxs</li><li data-line="6">Prognosis: often chronic and progressive, until bedridden. Survival is 3x longer than with multiple myeloma</li></ul></div><div><p>Treatment:</p></div><div><ul><li data-line="0">cyclophosphamide and prednisone to cool off the cytokine abnormalities</li><li data-line="1">autologous stem cell transplant</li></ul></div><div><p><a data-tooltip-position="top" aria-label="https://clinicalproblemsolving.us19.list-manage.com/track/click?u=f017866e70560792a7168318e&amp;id=66d95c2c98&amp;e=fe53a453ff" rel="noopener" class="external-link" href="https://clinicalproblemsolving.us19.list-manage.com/track/click?u=f017866e70560792a7168318e&amp;id=66d95c2c98&amp;e=fe53a453ff" target="_blank">POEMS syndrome</a>&nbsp;is a rare paraneoplastic disease associated with an underlying plasma cell dyscrasia and stands for polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes. Other important features not highlighted by this acronym include papilledema, extravascular volume overload, elevated vascular endothelial growth factor (VEGF) levels, sclerotic bone lesions, erthrocytosis, and thrombocytosis. Additionally, a variant of POEMS syndrome is associated with Castleman’s disease.</p></div><div><p>The&nbsp;<strong>two&nbsp;**</strong>mandatory&nbsp;*<strong>*major criteria&nbsp;</strong>for POEMS Syndrome&nbsp;are&nbsp;<strong>polyradiculoneuropathy</strong>&nbsp;and&nbsp;<strong>monoclonal plasma cell disorder.&nbsp;</strong></p></div><div><p>There are many other signs and symptoms outside of the POEMS acronym (see attached chart).</p></div><div><p></p><div src="lib\media\1a5a1731ee2afc3d9f369e3145c29286.jpg" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\1a5a1731ee2afc3d9f369e3145c29286.jpg"></div><br>Dispenzieri A. How I Treat POEMS Syndrome. Blood. Jun 2012; 119(24):5650-5658.<p></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">POEMS Syndrome</div></div><div class="canvas-node" style="z-index:13;transform:translate(600px,-684px);width:400px;height:400px;--canvas-node-width:400px;--canvas-node-height:400px"><div class="canvas-node-container"><div class="canvas-node-content markdown-embed is-loaded"><div class="markdown-embed-content node-insert-event"><div class="markdown-preview-view markdown-rendered node-insert-event show-indentation-guide allow-fold-headings allow-fold-lists"><div class="markdown-preview-sizer markdown-preview-section" style="padding-bottom:0"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> AL amyloidosis
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-07-25 03:19:18Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-05-21 17:46:35Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p>Epidemiology</p></div><div><p><span width="475" alt="WhatsApp Image 2023-06-23 at 13.11.07.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.11.07.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.11.07.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.11.07.jpg" style="max-width:100%"></span></p></div><div><p><strong>Most common forms of systemic amyloidosis</strong></p></div><div><p>AL amyloidosis may co-occur with multiple myeloma approximately 10% of the time</p></div><div><p>The plasma cell clone in AL amyloidosis is typically smaller and not as proliferative as in myeloma;</p></div><div><p>these clonal cells secrete light chains predominantly (but not exclusively) of the lambda type.</p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.08.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.39.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.08.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.39.jpg" style="max-width:100%"></span></p></div><div><p><span width="450" alt="WhatsApp Image 2023-06-23 at 13.13.25.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.13.25.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.13.25.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.13.25.jpg" style="max-width:100%"></span></p></div><div><p>Pathophysiology</p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.16.20.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.16.20.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.16.20.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.16.20.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="600" alt="../_resources/bf80dd8f4263b9d0c0ce6b04043f9ad0.png" src="lib\media\bf80dd8f4263b9d0c0ce6b04043f9ad0.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/bf80dd8f4263b9d0c0ce6b04043f9ad0.png" src="lib\media\bf80dd8f4263b9d0c0ce6b04043f9ad0.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/43bbb381ae4337f39ec30708df86ea3f.png" src="lib\media\43bbb381ae4337f39ec30708df86ea3f.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/43bbb381ae4337f39ec30708df86ea3f.png" src="lib\media\43bbb381ae4337f39ec30708df86ea3f.png" style="max-width:100%"></div><p></p></div><div><p><strong>Symptoms of amyloidosis&nbsp;</strong></p></div><div><ul><li data-line="0">nephrotic-range proteinuria</li><li data-line="1">heart failure with preserved ejection fraction: myocardial wall thickening with low-voltage electrocardiography waveforms<ul><li data-line="2">Tempo of onset (senile is slower)</li><li data-line="3"></li></ul></li><li data-line="4">a gradual decrease in the need for antihypertensive drugs</li><li data-line="5">nondiabetic peripheral neuropathy (ascending, symmetrical with approximately 50% having antecedent carpal tunnel syndrome)</li><li data-line="6">hepatomegaly with alkaline phosphatase elevation</li><li data-line="7">noninfectious chronic diarrhea</li><li data-line="8">erectile or bladder dysfunction</li></ul></div><div><p><span width="475" alt="WhatsApp Image 2023-06-23 at 13.20.35 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.20.35-1.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.20.35 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.20.35-1.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="500" alt="../_resources/e2b176b5344903f9b8d26b23f14a7e5a.png" src="lib\media\e2b176b5344903f9b8d26b23f14a7e5a.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e2b176b5344903f9b8d26b23f14a7e5a.png" src="lib\media\e2b176b5344903f9b8d26b23f14a7e5a.png" style="max-width:100%"></div><p></p></div><div><p>Case: 60 presents with fluid overload, diffuse mucocutaneoux bleeding, PT and PTT prolonged/corrects with mixing, factor X level markedly low</p></div><div><ul><li data-line="0">Amyloid fibrils absorb factor X leading to acquired deficiency</li><li data-line="1">Screening: IFE, SPEP, light chain</li><li data-line="2">Troponin, NT pro BNP for cardiac risk stratification</li></ul></div><div><p><strong>DIAGNOSIS</strong></p></div><div><p><span width="475" alt="WhatsApp Image 2023-06-23 at 13.21.44.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.21.44.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.21.44.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.21.44.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="500" alt="../_resources/fccca58da12ef4a64174d1aa710a2b62.png" src="lib\media\fccca58da12ef4a64174d1aa710a2b62.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/fccca58da12ef4a64174d1aa710a2b62.png" src="lib\media\fccca58da12ef4a64174d1aa710a2b62.png" style="max-width:100%"></div><p></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.25.03.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.03.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.25.03.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.03.jpg" style="max-width:100%"></span></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.25.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.39.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.25.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.39.jpg" style="max-width:100%"></span></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.08.40 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40-1.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.08.40 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40-1.jpg" style="max-width:100%"></span></p></div><div><p>Suspect AL amyloidosis: HFpEF, nephrotic syndrome, hepatomegaly, M protein L &gt; K, tissue diagnosis (fat pad &nbsp;biopsy or organ directed biopsy). Risk stratify with troponin, proBNP.</p></div><div><ul><li data-line="0">Transplant eligible: ASCT</li><li data-line="1">Non-eligible: dara+cyborD, goal dFLC &lt; 40 (ideally &lt; 10)</li></ul></div><div><p></p><div width="500" alt="../_resources/ac187c8cdc8becb778ba20e074b1dccc.png" src="lib\media\ac187c8cdc8becb778ba20e074b1dccc.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ac187c8cdc8becb778ba20e074b1dccc.png" src="lib\media\ac187c8cdc8becb778ba20e074b1dccc.png" style="max-width:100%"></div><p></p></div><div><p><strong>Organ involvement</strong></p></div><div><p><strong>Renal amyloidosis</strong><br></p><div width="475" alt="../_resources/09e3e05e90ed29bba24cee9fded7ef8c.png" src="lib\media\09e3e05e90ed29bba24cee9fded7ef8c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/09e3e05e90ed29bba24cee9fded7ef8c.png" src="lib\media\09e3e05e90ed29bba24cee9fded7ef8c.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/e44b7ef383ee01dbdfc7ac9491daf1c5.png" src="lib\media\e44b7ef383ee01dbdfc7ac9491daf1c5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e44b7ef383ee01dbdfc7ac9491daf1c5.png" src="lib\media\e44b7ef383ee01dbdfc7ac9491daf1c5.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/5dd9df0194c95c5a8eaa037d79ca67d5.png" src="lib\media\5dd9df0194c95c5a8eaa037d79ca67d5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5dd9df0194c95c5a8eaa037d79ca67d5.png" src="lib\media\5dd9df0194c95c5a8eaa037d79ca67d5.png" style="max-width:100%"></div><p></p></div><div><p><strong>Approach to AL amyloidosis</strong></p></div><div><p></p><div width="500" alt="../_resources/00f069da4949ca5c1201c9a116b03acb.png" src="lib\media\00f069da4949ca5c1201c9a116b03acb.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/00f069da4949ca5c1201c9a116b03acb.png" src="lib\media\00f069da4949ca5c1201c9a116b03acb.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Maintenance not typically used but can be in select patients</li></ul></div><div><p><strong>Risk stratification</strong></p></div><div><p>Cardiac risk stratification</p></div><div><p></p><div width="500" alt="../_resources/06555165b529e159e682a314d152d328.png" src="lib\media\06555165b529e159e682a314d152d328.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/06555165b529e159e682a314d152d328.png" src="lib\media\06555165b529e159e682a314d152d328.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/968916755357260cb1324a33dfdfcfc2.png" src="lib\media\968916755357260cb1324a33dfdfcfc2.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/968916755357260cb1324a33dfdfcfc2.png" src="lib\media\968916755357260cb1324a33dfdfcfc2.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/cfc722491bfbe3c7079ea7ceb985b461.png" src="lib\media\cfc722491bfbe3c7079ea7ceb985b461.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/cfc722491bfbe3c7079ea7ceb985b461.png" src="lib\media\cfc722491bfbe3c7079ea7ceb985b461.png" style="max-width:100%"></div><p></p></div><div><p>Risk stratification models</p></div><div style="overflow-x:auto"><table><thead><tr><th></th><th></th><th></th></tr></thead><tbody><tr><td>European modification of 2004 Mayo clinic</td><td><div width="425" alt="../_resources/7effebe57c23283ed9aa6e80157b2e81.png" src="lib\media\7effebe57c23283ed9aa6e80157b2e81.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7effebe57c23283ed9aa6e80157b2e81.png" src="lib\media\7effebe57c23283ed9aa6e80157b2e81.png" style="max-width:100%"></div></td><td>based on NT-proBNP and cardiac troponin (cTn). Troponin I was used in this figure. Cutoffs are 332 ng/L for NT-proBNP and 100, 35, and 54 ng/L for cTnI, cTnT, and high-sensitivity cTnT, respectively. B-type natriuretic peptide can substitute for NT-proBNP in the staging system (cutoff, 81 ng/L). Patients with stage I, II, and III have 0, 1, and 2 markers above the cutoff, respectively. Patients with stage III are classified as stage IIIa or IIIb according to concentration of NT-proBNP below or above 8500 ng/L</td></tr><tr><td>Revised Mayo clinic</td><td><div src="lib\media\2ea2e0936dfd0fcc52bfe0f18f3f504d.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\2ea2e0936dfd0fcc52bfe0f18f3f504d.png"></div></td><td>NT-proBNP, cTn, and dFLC. Cutoffs are 1800 ng/L for NT-proBNP and 25 ng/L for cTnT. Troponin I can substitute for cTnT (cutoff, 70 ng/L)38 and was used in this figure. Patients with stage I, II, III, and IV have 0, 1, 2, and 3 markers above the cutoff, respectively.</td></tr><tr><td>Renal staging</td><td><div src="lib\media\c18f10c9973fc78b1ddb9f285ee36240.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c18f10c9973fc78b1ddb9f285ee36240.png"></div></td><td>(eGFR) and proteinuria. Cutoffs are 50 mL/ min per 1.73 m2 for eGFR and 5 g/24 h for proteinuria. Patients with stage I, II, and III have 0, 1, and 2 markers above the cutoff, respectively.</td></tr></tbody></table></div><div><p>Bone marrow involvement</p></div><div><p></p><div width="500" alt="../_resources/3b28140f30afec2feaaf983c8d1a26ed.png" src="lib\media\3b28140f30afec2feaaf983c8d1a26ed.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/3b28140f30afec2feaaf983c8d1a26ed.png" src="lib\media\3b28140f30afec2feaaf983c8d1a26ed.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Plasma cell burden = myeloma like -&gt; PFS better in transplant arm</li></ul></div><div><p>Multivariate predictors for survival<br></p><div width="500" alt="../_resources/4e396385318255ae4437d59b55b6de20.png" src="lib\media\4e396385318255ae4437d59b55b6de20.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4e396385318255ae4437d59b55b6de20.png" src="lib\media\4e396385318255ae4437d59b55b6de20.png" style="max-width:100%"></div><p></p></div><div><p><strong>RESPONSE assessment</strong></p></div><div><p></p><div width="500" alt="../_resources/2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" src="lib\media\2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" src="lib\media\2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">dFLC: difference between involved and uninvolved free light chain</li><li data-line="1">Previously: achieving a hematologic very good partial response was lowering the difference in free light chains to less than 40 mg/L was sufficient; now the goal has shifted to reaching a complete response (difference in free light chains &lt; 10 mg/L)</li></ul></div><div><p>Staging</p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.08.40.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.08.40.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40.jpg" style="max-width:100%"></span></p></div><div><p><strong>TREATMENT</strong></p></div><div><p></p><div width="500" alt="../_resources/6b6a6057a96e49f2e364fe8db4a134a4.png" src="lib\media\6b6a6057a96e49f2e364fe8db4a134a4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/6b6a6057a96e49f2e364fe8db4a134a4.png" src="lib\media\6b6a6057a96e49f2e364fe8db4a134a4.png" style="max-width:100%"></div><p></p></div><div><p><strong>Phase III ANDROMEDA </strong>study comparing daratumumab with cyclophosphamide/bortezomib/dexamethasone to cyclo- phosphamide/bortezomib/dexamethasone</p></div><div><ul><li data-line="0">daratumumab resulted in a significant improvement in the overall response rate (92% vs. 77%),&nbsp;doubling of organ responses at 6 months (cardiac response, 42% vs. 22%; renal response, 53% vs. 24%), and a significant improvement in survival free from major organ deterioration or hematologic progression</li><li data-line="1"><div width="500" alt="../_resources/0a8452c35e9fde8ec04b264d3b59f958.png" src="lib\media\0a8452c35e9fde8ec04b264d3b59f958.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/0a8452c35e9fde8ec04b264d3b59f958.png" src="lib\media\0a8452c35e9fde8ec04b264d3b59f958.png" style="max-width:100%"></div></li><li data-line="2"><div src="lib\media\3fefc709142f0328a84cdaa31ec6335c.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\3fefc709142f0328a84cdaa31ec6335c.png"></div></li></ul></div><div><p><strong>TREATMENT ALGORITHM</strong></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.40.46.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.40.46.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.40.46.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.40.46.jpg" style="max-width:100%"></span></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.41.26.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.41.26.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.41.26.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.41.26.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="500" alt="../_resources/ba9a58c87bec4c864bbda26889adafae.png" src="lib\media\ba9a58c87bec4c864bbda26889adafae.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ba9a58c87bec4c864bbda26889adafae.png" src="lib\media\ba9a58c87bec4c864bbda26889adafae.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/007fae65ad4e5cae782bde94fb0e3adf.png" src="lib\media\007fae65ad4e5cae782bde94fb0e3adf.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/007fae65ad4e5cae782bde94fb0e3adf.png" src="lib\media\007fae65ad4e5cae782bde94fb0e3adf.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/f0a5ace04c11e1eb13c2c1278abc2bf3.png" src="lib\media\f0a5ace04c11e1eb13c2c1278abc2bf3.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/f0a5ace04c11e1eb13c2c1278abc2bf3.png" src="lib\media\f0a5ace04c11e1eb13c2c1278abc2bf3.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/ce957bfaf534901c9275777356a50a7b.png" src="lib\media\ce957bfaf534901c9275777356a50a7b.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ce957bfaf534901c9275777356a50a7b.png" src="lib\media\ce957bfaf534901c9275777356a50a7b.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">dara-CyBorD: should response after 2 cycles, if do not, change strategy</li></ul></div><div><p></p><div width="500" alt="../_resources/5b2d2f2e7478f1e75198cf6615275b3b.png" src="lib\media\5b2d2f2e7478f1e75198cf6615275b3b.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5b2d2f2e7478f1e75198cf6615275b3b.png" src="lib\media\5b2d2f2e7478f1e75198cf6615275b3b.png" style="max-width:100%"></div><br><div width="575" alt="../_resources/092f200e258343072eec355e80065dc7.png" src="lib\media\092f200e258343072eec355e80065dc7.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/092f200e258343072eec355e80065dc7.png" src="lib\media\092f200e258343072eec355e80065dc7.png" style="max-width:100%"></div><p></p></div><div><p><strong>Why transplant?</strong></p></div><div><p>TRANSPLANT ELIGIBLE</p></div><div><p></p><div width="500" alt="../_resources/4259f1d0336d7278e450c445d2db3f97.png" src="lib\media\4259f1d0336d7278e450c445d2db3f97.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4259f1d0336d7278e450c445d2db3f97.png" src="lib\media\4259f1d0336d7278e450c445d2db3f97.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Melphalan dosing based on age and organ involvement</li><li data-line="1">If achieve CR (~33% pts) after ASCT: observation</li><li data-line="2">If do not achieve CR: bortezomib can achieve 60% CR</li><li data-line="3">Caveat: these are transplant eligible patients</li></ul></div><div><p></p><div width="475" alt="../_resources/e5de8e38cec8d36fdce11932b7a620ef.png" src="lib\media\e5de8e38cec8d36fdce11932b7a620ef.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e5de8e38cec8d36fdce11932b7a620ef.png" src="lib\media\e5de8e38cec8d36fdce11932b7a620ef.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/361c50683aeac2b01cf81d2a213c07d4.png" src="lib\media\361c50683aeac2b01cf81d2a213c07d4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/361c50683aeac2b01cf81d2a213c07d4.png" src="lib\media\361c50683aeac2b01cf81d2a213c07d4.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">D-VCd higher CR than ASCT</li></ul></div><div><p><strong>Transplant eligibility&nbsp;</strong></p></div><div><p></p><div width="475" alt="../_resources/832b4dbb557726e80ee2d0038f0b1f45.png" src="lib\media\832b4dbb557726e80ee2d0038f0b1f45.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/832b4dbb557726e80ee2d0038f0b1f45.png" src="lib\media\832b4dbb557726e80ee2d0038f0b1f45.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0"><div width="400" alt="../_resources/a62aaa76abdc85dd90393141cb96d85a.png" src="lib\media\a62aaa76abdc85dd90393141cb96d85a.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/a62aaa76abdc85dd90393141cb96d85a.png" src="lib\media\a62aaa76abdc85dd90393141cb96d85a.png" style="max-width:100%"></div></li><li data-line="1">Transplant for those already on dialysis then amyloid</li><li data-line="2">Conditions associated with excess mortality<ul><li data-line="3">3 organ involvement is barrier to transplantation due to excess mortality: volume distribution becomes an issue</li><li data-line="4">Significant cardiac involvement with elevated BNP: high risk of cardiac complications</li><li data-line="5">Liver involvement: risk of VOD following transplant</li><li data-line="6">GI involvement: bleeding with transplant</li></ul></li></ul></div><div><p><strong>Comparing between induction regimens: D-VCd</strong><br></p><div width="500" alt="../_resources/d956c7cbe3c1ab718c498e1c70637e93.png" src="lib\media\d956c7cbe3c1ab718c498e1c70637e93.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/d956c7cbe3c1ab718c498e1c70637e93.png" src="lib\media\d956c7cbe3c1ab718c498e1c70637e93.png" style="max-width:100%"></div><p></p></div><div><p><strong>Outcome after transplant</strong></p></div><div><p></p><div width="500" alt="../_resources/385b52bd1edf780fbf9702966e96ea36.png" src="lib\media\385b52bd1edf780fbf9702966e96ea36.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/385b52bd1edf780fbf9702966e96ea36.png" src="lib\media\385b52bd1edf780fbf9702966e96ea36.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/5b33eb30bcf76ec5b3342969ebb31d8c.png" src="lib\media\5b33eb30bcf76ec5b3342969ebb31d8c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5b33eb30bcf76ec5b3342969ebb31d8c.png" src="lib\media\5b33eb30bcf76ec5b3342969ebb31d8c.png" style="max-width:100%"></div><p></p></div><div><p>Melphalan dose</p></div><div><ul><li data-line="0"><div width="500" alt="../_resources/86fb46201948b9450231061359c4eaf7.png" src="lib\media\86fb46201948b9450231061359c4eaf7.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/86fb46201948b9450231061359c4eaf7.png" src="lib\media\86fb46201948b9450231061359c4eaf7.png" style="max-width:100%"></div></li></ul></div><div><p></p><div width="500" alt="../_resources/12e4580b9f7f5259bec3cbc52a9d81c5.png" src="lib\media\12e4580b9f7f5259bec3cbc52a9d81c5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/12e4580b9f7f5259bec3cbc52a9d81c5.png" src="lib\media\12e4580b9f7f5259bec3cbc52a9d81c5.png" style="max-width:100%"></div><p></p></div><div><p><strong>Organ transplant for AL amyloidosis</strong></p></div><div><p></p><div width="500" alt="../_resources/1ccdfdcba8b2ef3890bf76eed6aebe30.png" src="lib\media\1ccdfdcba8b2ef3890bf76eed6aebe30.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1ccdfdcba8b2ef3890bf76eed6aebe30.png" src="lib\media\1ccdfdcba8b2ef3890bf76eed6aebe30.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Median time to renal recovery is 9 months</li></ul></div><div><p>Heart transplant: viable if can achieve hematologic response<br></p><div width="500" alt="../_resources/552721f2ffa069c63776c3a8a645e807.png" src="lib\media\552721f2ffa069c63776c3a8a645e807.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/552721f2ffa069c63776c3a8a645e807.png" src="lib\media\552721f2ffa069c63776c3a8a645e807.png" style="max-width:100%"></div><p></p></div><div><p><strong>Transplant ineligible</strong></p></div><div><p><strong>First line therapy</strong></p></div><div><p></p><div width="500" alt="../_resources/c56b422c58ec19feda13973a6e3cf9e0.png" src="lib\media\c56b422c58ec19feda13973a6e3cf9e0.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/c56b422c58ec19feda13973a6e3cf9e0.png" src="lib\media\c56b422c58ec19feda13973a6e3cf9e0.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/e59ebabc7397cee8ea7e4d22387b8f99.png" src="lib\media\e59ebabc7397cee8ea7e4d22387b8f99.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e59ebabc7397cee8ea7e4d22387b8f99.png" src="lib\media\e59ebabc7397cee8ea7e4d22387b8f99.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Organ response is usually delayed</li></ul></div><div><p></p><div width="500" alt="../_resources/bd5b889b13963073f178a48453f42aaa.png" src="lib\media\bd5b889b13963073f178a48453f42aaa.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/bd5b889b13963073f178a48453f42aaa.png" src="lib\media\bd5b889b13963073f178a48453f42aaa.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/c34a2696aed082b78f89bfd1fd2f5ebb.png" src="lib\media\c34a2696aed082b78f89bfd1fd2f5ebb.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/c34a2696aed082b78f89bfd1fd2f5ebb.png" src="lib\media\c34a2696aed082b78f89bfd1fd2f5ebb.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/2271db9da5947bf735f22b1ffcccbc92.png" src="lib\media\2271db9da5947bf735f22b1ffcccbc92.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/2271db9da5947bf735f22b1ffcccbc92.png" src="lib\media\2271db9da5947bf735f22b1ffcccbc92.png" style="max-width:100%"></div><p></p></div><div><p>Risk adapted<br></p><div width="400" alt="../_resources/eec459d70d52836e06e5e5c1ded52d8e.png" src="lib\media\eec459d70d52836e06e5e5c1ded52d8e.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/eec459d70d52836e06e5e5c1ded52d8e.png" src="lib\media\eec459d70d52836e06e5e5c1ded52d8e.png" style="max-width:100%"></div><p></p></div><div><p>Clone adapted<br></p><div width="500" alt="../_resources/108575c79662dd08cb0907981beb270d.png" src="lib\media\108575c79662dd08cb0907981beb270d.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/108575c79662dd08cb0907981beb270d.png" src="lib\media\108575c79662dd08cb0907981beb270d.png" style="max-width:100%"></div><p></p></div><div><p>Patient adapted<br></p><div width="500" alt="../_resources/5ee6ad8d2bd92c009492771a1505d142.png" src="lib\media\5ee6ad8d2bd92c009492771a1505d142.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5ee6ad8d2bd92c009492771a1505d142.png" src="lib\media\5ee6ad8d2bd92c009492771a1505d142.png" style="max-width:100%"></div><p></p></div><div><p><strong>Time to response is important</strong></p></div><div><p></p><div width="500" alt="../_resources/871e948140f4d0d28de2f57a6c8284ab.png" src="lib\media\871e948140f4d0d28de2f57a6c8284ab.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/871e948140f4d0d28de2f57a6c8284ab.png" src="lib\media\871e948140f4d0d28de2f57a6c8284ab.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Difference in outcome between 1 month and 3 month hematologic response</li></ul></div><div><p><strong>Consider primary refractory if do not response within 2 cycles</strong><br></p><div width="500" alt="../_resources/1a32958de2ea5e2dd049f7230300d7cd.png" src="lib\media\1a32958de2ea5e2dd049f7230300d7cd.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1a32958de2ea5e2dd049f7230300d7cd.png" src="lib\media\1a32958de2ea5e2dd049f7230300d7cd.png" style="max-width:100%"></div><p></p></div><div><p><strong>SUPPORTIVE care</strong></p></div><div><p></p><div width="500" alt="../_resources/1c8599638618f8a8ba50624b52af0aa4.png" src="lib\media\1c8599638618f8a8ba50624b52af0aa4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1c8599638618f8a8ba50624b52af0aa4.png" src="lib\media\1c8599638618f8a8ba50624b52af0aa4.png" style="max-width:100%"></div><p></p></div><div><p><strong>Relapse</strong></p></div><div><p></p><div width="500" alt="../_resources/ba93464ec99beb4fe2b9e1e5b41c0801.png" src="lib\media\ba93464ec99beb4fe2b9e1e5b41c0801.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ba93464ec99beb4fe2b9e1e5b41c0801.png" src="lib\media\ba93464ec99beb4fe2b9e1e5b41c0801.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/06b90dce58705e44715e51d5613e0842.png" src="lib\media\06b90dce58705e44715e51d5613e0842.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/06b90dce58705e44715e51d5613e0842.png" src="lib\media\06b90dce58705e44715e51d5613e0842.png" style="max-width:100%"></div><p></p></div><div><p><strong>Therapeutic options&nbsp;</strong></p></div><div><ul><li data-line="0">Re-challenge with cybor-d x 9 cycles</li><li data-line="1">Daratumumab currently not funded in Ontario for amyloid</li></ul></div><div><p></p><div width="500" alt="../_resources/eb0d16e8e57f9fc3b9773fb7a9b63631.png" src="lib\media\eb0d16e8e57f9fc3b9773fb7a9b63631.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/eb0d16e8e57f9fc3b9773fb7a9b63631.png" src="lib\media\eb0d16e8e57f9fc3b9773fb7a9b63631.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/a10736147f8d4c4333a67ed3826ec01d.png" src="lib\media\a10736147f8d4c4333a67ed3826ec01d.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/a10736147f8d4c4333a67ed3826ec01d.png" src="lib\media\a10736147f8d4c4333a67ed3826ec01d.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/04a435c1f33196ea33cfbe4c91c7ef19.png" src="lib\media\04a435c1f33196ea33cfbe4c91c7ef19.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/04a435c1f33196ea33cfbe4c91c7ef19.png" src="lib\media\04a435c1f33196ea33cfbe4c91c7ef19.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Hematologic progression occurs months before organ progression: should reinitiate treatment</li></ul></div><div><p></p><div width="500" alt="../_resources/11fefc1c3c36b71484692f6990684b2a.png" src="lib\media\11fefc1c3c36b71484692f6990684b2a.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/11fefc1c3c36b71484692f6990684b2a.png" src="lib\media\11fefc1c3c36b71484692f6990684b2a.png" style="max-width:100%"></div><br>Also light chain stabilizers<p></p></div><div><p>Immunomodulatory agents: lenalidomide - risk of renal dysfunction</p></div><div><p></p><div width="500" alt="../_resources/102b9d4c611e2415ba130f2c59ef887f.png" src="lib\media\102b9d4c611e2415ba130f2c59ef887f.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/102b9d4c611e2415ba130f2c59ef887f.png" src="lib\media\102b9d4c611e2415ba130f2c59ef887f.png" style="max-width:100%"></div><p></p></div><div><p>Daratumumab<br></p><div width="500" alt="../_resources/7a564437f1003d9530e5eddf0594a07e.png" src="lib\media\7a564437f1003d9530e5eddf0594a07e.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7a564437f1003d9530e5eddf0594a07e.png" src="lib\media\7a564437f1003d9530e5eddf0594a07e.png" style="max-width:100%"></div><p></p></div><div><p>Others</p></div><div><p></p><div width="500" alt="../_resources/228f7cb2a670a5cc33d595595bd7a6fe.png" src="lib\media\228f7cb2a670a5cc33d595595bd7a6fe.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/228f7cb2a670a5cc33d595595bd7a6fe.png" src="lib\media\228f7cb2a670a5cc33d595595bd7a6fe.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="475" alt="../_resources/1806f42776c02127b8de2502131be559.png" src="lib\media\1806f42776c02127b8de2502131be559.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1806f42776c02127b8de2502131be559.png" src="lib\media\1806f42776c02127b8de2502131be559.png" style="max-width:100%"></div><p></p></div><div><p><strong>Anti-fibrillar antibodies</strong><br></p><div width="500" alt="../_resources/4cffb0aecfccd6af17d54675580b9c8b.png" src="lib\media\4cffb0aecfccd6af17d54675580b9c8b.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4cffb0aecfccd6af17d54675580b9c8b.png" src="lib\media\4cffb0aecfccd6af17d54675580b9c8b.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/4da639df1ae48d8c1ff4835998d00f5c.png" src="lib\media\4da639df1ae48d8c1ff4835998d00f5c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4da639df1ae48d8c1ff4835998d00f5c.png" src="lib\media\4da639df1ae48d8c1ff4835998d00f5c.png" style="max-width:100%"></div><p></p></div><div><p>Summary<br></p><div width="500" alt="../_resources/eaf8c12a7aeaed175ded5f9128dfedc7.png" src="lib\media\eaf8c12a7aeaed175ded5f9128dfedc7.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/eaf8c12a7aeaed175ded5f9128dfedc7.png" src="lib\media\eaf8c12a7aeaed175ded5f9128dfedc7.png" style="max-width:100%"></div><p></p></div><div><p><strong>SUPPORTIVE therapy in AL amyloidosis</strong><br></p><div width="500" alt="../_resources/3e880d3002d4696ec5c276fa69c39e72.png" src="lib\media\3e880d3002d4696ec5c276fa69c39e72.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/3e880d3002d4696ec5c276fa69c39e72.png" src="lib\media\3e880d3002d4696ec5c276fa69c39e72.png" style="max-width:100%"></div><p></p></div></div></div></div><div class="markdown-embed-content node-insert-event" style="display:none"></div></div><div class="canvas-node-content-blocker"></div></div><div class="canvas-node-label">AL Amyloidosis</div></div></div></div></div></div><div class="sidebar-right sidebar"><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div class="graph-view-wrapper"><div class="sidebar-section-header">Interactive Graph</div><div class="graph-view-placeholder"><div class="graph-view-container"><div class="graph-icon graph-expand" role="button" aria-label="Expand" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><line x1="7" y1="17" x2="17" y2="7"></line><polyline points="7 7 17 7 17 17"></polyline></svg></div><canvas id="graph-canvas" width="512px" height="512px"></canvas></div></div></div><div class="tree-container outline-tree" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Table Of Contents</span><button class="clickable-icon collapse-tree-button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"></div></div></div></div></div></div></div></div></body></html>